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1. INTRODUCTION 
1.1 THE IMMUNE SYSTEM - BASIC IMMUNOLOGICAL CONCEPTS 
The immune system is a highly effective defense system occupied with the important task of 
protecting the body against threats from the outside world, such as harmful microorganisms 
as well as threats from within the body like cancer cells or damaged tissue. To accomplish 
this task, the immune system must be able to separate harmful from innocent substances and 
initiate effective immune responses when necessary1. If this process fails, the immune system 
faces the risk of inadequate responses to infections, in addition to mounting attack against 
healthy tissue (autoimmune diseases) or harmless substances (allergic diseases)2. 
 
The immune system can be divided into two arms; the innate and the adaptive component. 
The innate immune system is the first line of defense, and involves the epithelial barrier, a 
humoral component (the complement system and cytokines), and a variety of different 
hematopoietic immune cells like mast cells, granulocytes, the mononuclear phagocytic 
system (MPS), (dendritic cells, monocytes and macrophages), among others2.  
 
The main task of the innate immune system is to initiate a swift and effective response upon 
recognition of harmful substances3. The adaptive immune system is slower to respond, but 
characterized by higher degree of specificity and immunological memory. The adaptive 
component consists of antibody responses carried out by B cells, and cell-mediated responses 
mediated by T cells. In an optimal response to a potential threat, the innate and adaptive parts 
of the immune system cooperate to mount a rapid and effective immune reaction, while at the 
same time develop memory for later encounters with the same antigen3, 4. 
 
Dendritic cells (DCs), central to this thesis, act as the bridge between the innate and adaptive 
part of the immune system, consequently these cells face the important task of deciding when 
to trigger an immune response in the presence of danger – and when to “keep calm and carry 
on”, thus maintaining tolerance to harmless substances and self molecules3.  
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1.2 THE MUCOSAL IMMUNE SYSTEM IN THE UPPER AIRWAYS  
The upper airway mucosa is in close contact with the external environment, and is exposed to 
a large variety of antigens constantly challenging the immune system to mount effective 
protection.  
 
 
Figure 1. Histology of normal nasal mucosa. Epithelial layer with ciliated epithelium. Basement 
membrane separating the epithelial layer from the lamina propria. Lamina propria with vessels, glands 
and immune cells.  
Adapted from www.humpath.com – Human pathology 
 
The nasal mucosa is covered by a layer of pseudostratified columnar epithelium, including 
scattered goblet cells (Figure 1). The lamina propria contains a large number of glands, where 
the glandular epithelium produce mucus and is important for translocating immunoglobulin A 
(IgA) and IgM, produced by lamina propria-resident plasma cells. The goblet cells and the 
glands are responsible for a protective layer of mucus, which together with secretory Igs and 
ciliated epithelial cells are important for removal of foreign substances.  
 
The epithelial cells comprise a first line of defense of the mucosal immune system. In 
addition to being a physical barrier, epithelial cells express a broad range of pattern 
recognition receptors (PRRs), that can detect pathogen associated molecular patterns 
(PAMPs) expressed by microbes, and damage-associated molecular patterns (DAMPs) 
Respiratory epithelium
Basement membrane
Lamina propria
Blood vessels
Glands
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released upon tissue damage, cell death or cellular stress. Activation of these PRRs leads to 
the secretion of antimicrobial peptides as well as cytokines and chemokines that attract and 
activate immune cells that reside underneath and within the epithelial surface5. Crosstalk 
between epithelial cells and immune cells is crucial for the immunological barrier function, 
and aberrant crosstalk may result in inflammatory disease at mucosal surfaces6. In addition, 
commensal microorganisms contribute to host defense through metabolic competition and by 
enforcing the host’s immune barrier7. 
 
1.2.1 IMMUNE CELLS IN THE NASAL MUCOSA 
The lamina propria contains a dense network of immune cells with various functions. 
 
Mast cells 
Mast cells are found in all mucosal tissues, and play a central role in inflammatory and 
immediate allergic reactions. They harbor vast amounts of potent inflammatory mediators 
that can be released swiftly and mediate inflammatory responses by blood vessel dilation, 
increased vascular permeability and recruitment of immune cells to the tissue.  
 
Mast cells respond to antigenic stimulation through cross-linking of IgE bound to the high 
affinity receptors for IgE (FcεRI). Upon activation, mast cells release either prestored 
mediators such as histamine and proteases, or newly generated mediators such as eicosanoids, 
cytokines and chemokines8. In addition to their central role in allergic responses, mast cells 
are recognized as effector cells in various pathological conditions including chronic 
inflammation, autoimmune diseases, cardiovascular disorders, bacterial clearance and 
resistance to infections with parasites9, 10. Their diverse nature is reflected in the vast amounts 
of mediators that can be released from these cells11.  
 
Eosinophils 
Eosinophils are involved in the initiation and maintenance of diverse inflammatory responses. 
In particular, they have long been associated with parasitic and allergen driven inflammation, 
and the infiltration of eosinophils to the airways is one of the hallmark characteristics of 
allergic asthma.  
 
4 
Eosinophils are quickly recruited to sites of inflammation where they release proinflammatoy 
cytokines, chemokines, growth factors, lipid mediators and cytotoxic granules. Some of these 
substances are pre-stored and can be released rapidly within minutes to initiate inflammatory 
responses. Eosinophils were shown to be a major source of the cytokine interleukin 4 (IL-4), 
and this may serve as a major initial source of IL-4 required for the differentiation of naïve T 
cells into T helper 2 (Th2)-cells, as will be described later12, 13.  
 
The mononuclear phagocyte system  
The MPS is defined as a family of cells comprising monocytes, DCs and macrophages14, 15. 
Macrophages and DCs are tissue-residing cells that express PRRs and are strategically 
situated underneath and within the epithelium of the mucosa and continuously scan the 
environment to sense potentially harmful antigens (Figure 2). Monocytes are mainly present 
in the circulation and may serve as precursor for tissue-residing macrophages and 
inflammatory DCs. They are all heterogeneous populations, and can differentiate into 
different functional subsets14. 
 
 
Figure 2. Immunohistochemistry of the main antigen presenting cell subsets of the upper airway 
mucosa.  
CD163+/CD14+ macrophages and CD1c+ DCs reside in the epithelium and in the lamina propria 
underneath the epithelial surfaces. Green: cytokeratin staining in epithelial cells, red: CD163 and 
CD1c respectively 
 
Monocytes and DCs are derived from a common bone marrow-derived hematopoietic stem 
cell (HSC) as will be described later. They differentiate into various subsets in response to 
different mediators that act as growth and differentiation factors16.  
 
CD163
cytokeratin
CD1c
cytokeratin
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Tissue-residing macrophages were initially thought to be derived from blood monocytes, 
however this notion has been challenged by the fact that in mice, a proportion of resident 
tissue macrophages arise from yolk sac and foetal liver precursors. These cells seed the tissue 
during embryonic development, and are able to proliferate and self-maintain locally17, 18, 19 , 20. 
However, the relative proportion of embryonic or monocytic origin to the tissue-resident 
macrophage population depends to a large extent on the tissue they reside in. For example, 
tissue-resident macrophages (microglia) in the brain seems to be exclusively derived from 
embryonic stem cells21, 22, while studies from the intestinal mucosa in mice have shown that 
the macrophage population requires constant replenishment from blood monocytes23, 24, 25, 26, 
27.  
 
In addition, the balance between monocyte- and stem cell derived macrophages may vary 
with inflammatory conditions and with age. Monocytes may be recruited in inflammatory 
conditions, furthermore in mice cardiac macrophages derived from embryonic precursors 
gradually lose their capacity to self-renew and are continually replaced by monocyte-derived 
macrophages even in the absence of inflammation28. How this correlates to the macrophage 
population in human tissues is unknown. Interestingly, recent work in our lab shows that in 
transplanted gut tissue between humans where immune cells can be traced as donor or 
recipient derived, all donor macrophages are replaced by recipient monocytes one year after 
transplantation. (Bujko et al, unpublished data).  
 
Macrophages are resident phagocytic cells that engulf and eliminate apoptotic cells, cellular 
debris and incoming pathogens15. In response to bacterial infections, macrophages capture 
and clear microorganisms and secrete pro-inflammatory molecules, thus playing a crucial role 
in host defense14. They are present in every tissue of the body, display great functional 
diversity, and are divided into subpopulations depending on their anatomical location. 
Macrophages perform important homeostatic functions by clearance of pathogens and toxins, 
as well as suppression of inflammation. Thus, macrophages contribute to the restoration of 
homeostasis following infection or injury29, 30.  
 
Tissue-resident macrophages may differentiate into different subsets depending on the signals 
they sense in their environment. Based on their function, macrophages are divided broadly 
into two categories; classical M1 and alternatively activated M2 macrophages. M1 
macrophages differentiate in response to interferon (IFN)-γ and lipopolysaccharide (LPS), 
6 
and are involved in inflammatory responses, pathogen clearance, and antitumor immunity. 
M2 macrophages take part in anti-inflammatory responses, wound healing, tumor progression 
and immunosupression31. This subset of macrophages can further be divided into four 
different subsets, one being M2a macrophages which differentiate upon stimulation with IL-4 
and IL-13 and are involved in Th2 responses, allergy and parasite clearance32, 33. These 
findings are primarily derived from in vitro experiments, thus the functions of M2 
macrophages in vivo remains to be determined. 
 
Monocytes circulate in the blood stream, and may replenish resident tissue macrophages 
under steady state as previously described. In response to tissue damage and inflammatory 
signals they move quickly to sites of inflammation and may differentiate into inflammatory 
macrophages and DCs22, 34.  
 
Two main human monocyte populations have been described based on the expression of the 
receptors CD14 and CD16; classical CD14+monocytes that are precursors of peripheral 
mononuclear phagocytes, and non-classical CD16+ monocytes that reside in the vascular 
lumen and survey endothelial integrity22, 35.  
 
Dendritic cells excel in antigen-presenting capacity and ability for migration to lymph nodes 
compared to monocytes and macrophages26. The presence of different mucosal DC subsets 
with distinct functional specialization will be discussed later. In case of encounter with a 
pathogen, tissue resident DCs take up pathogens by macropinocytosis or receptor-mediated 
phagocytosis and migrate via the lymphatics to regional lymph nodes, where they arrive as 
mature nonphagocytic DCs36. Here, the mature DCs activate antigen-specific naïve CD4+ 
helper T cells37 (Figure 3).  
 
DC-migration to lymph nodes is dependent on the chemokine receptor 7 (CCR7) and its 
ligands chemokine ligand 19 (CCL19) and CCL21, both during steady state and during 
inflammation38. In response to mediators of inflammation DCs up-regulate CCR7 and 
increase their capacity for lymph node migration. The importance of CCR7 for lymph node 
migration was demonstrated in studies where CCR7 deficient mice had a marked defect in 
DC migration to lymph nodes38. CCR7 and its ligands control DC chemotaxis towards 
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lymphatic capillaries and docking on the vessels. In the lymph nodes, CCR7 is critical for 
correct localization to the T cell zone, ensuring interplay between DCs and naïve T cells39. 
 
 
Figure 3. The adaptive immune response in the nasal mucosa is initiated by dendritic 
cells. Antigen is ingested by DCs in the tissue, transported to the lymph nodes and presented 
for naïve T cells (nT). Naïve T cells become activated; contribute to the activation of naïve B 
(nB) cells and both subsets may home back to the nasal mucosa as effector T cells (Teff) and 
plasma cells, respectively. 
 
Lymphocytes 
In draining lymph nodes, activated T cells interact with naïve B cells which subsequently 
differentiate into antibody-secreting plasmablasts that travel to the mucosal effector sites, and 
differentiate into plasma cells for antibody production and later encounter with the antigen40, 
41(Figure 3).  
 
Activated T cells undergo clonal proliferation in the lymph node, and may reside in the 
lymphoid tissues to activate more B cells, or exit the lymph nodes through efferent 
lymphatics and home to the mucosa as effector T cells in the process of an ongoing 
Epithelial cells 
Lymph node
Afferent lymph
nT
nB
Efferent lymph
Blood vessel
Plasma
blast
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Plasma
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inflammation. After the inflammation has been resolved, most effector T cells die, but a 
minority differentiate into memory T (TM) cells weeks after the resolution of inflammation.  
 
Different subsets of TM cells reside in different locations and perform distinct types of 
immune surveillance under homeostatic conditions. Resident memory T cells (TRM) reside in 
peripheral tissue and do not recirculate, central memory T cells (TCM) recirculate between 
lymphoid tissue and blood, and effector memory T (TEM) cells primarily recirculate between 
the blood and peripheral tissue42, 43.  
 
1.2.2 T-CELL PRIMING 
T cells mature in the thymus, where they undergo positive and negative selection to be able to 
recognize self major histocompatibility complex (MHC), but at the same time autoreactive 
clones are eliminated (central tolerance)44. 
 
After development in the thymus, naïve T cells migrate to secondary lymphoid organs where 
activation by DCs may take place45. Naïve CD4+T helper cells differentiate into different 
functional effector subsets depending on the signals they receive from antigen presenting 
cells (APCs) and the stimulatory cytokines that are present in the microenvironment during 
activation (Figure 4)46, 47, 48.  
 
The pathogen type and the local mediators from neighboring immune and stromal cells at the 
site of antigen capture are integrated by tissue-resident DCs which is important for the type of 
T-cell differentiation49. Thus, DCs determine, to a large extent, the adaptive immune response 
that is initiated in response to a specific pathogen via the signals by which they activate and 
differentiate naive T cells50. Through production of subset-specific cytokines these specific 
CD4+ helper T cells provide support to B lymphocytes and CD8+ cytotoxic T cells, and 
activate cells of the innate immune system46, 51.  
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Figure 4. Dendritic cells control the development of distinct T-cell responses. Antigen-specific 
naïve T cells are stimulated to expand in interaction with APCs expressing MHC class II / peptide. 
These T cells specialize to become distinct subsets and produce restricted patterns of cytokines, 
depending on the cytokine milieu and the signals they receive from the antigen presenting cell. 
Adapted from; Raphael I et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. 
Cytokine (2014),published ahead of print; http://www.sciencedirect.com/science/article/pii/S1043466614005390  
 
Following activation and differentiation, CD4+ helper T cells may migrate back to the 
mucosal effector sites as effector T cells to promote local immune responses (Figure 3)40, 
thus they are crucial for host defense. CD4+ helper T cells are also implicated in immune-
mediated diseases like allergy and autoimmune disease46.  
 
Naïve conventional CD4+ T cells may be polarized into several different effector subtypes; 
Th1, Th2, Th17, Th9, Th22, Tfh and inducible T-regulatory cells (Tregs), with specialized 
functions to control immune responses52. T-cell differentiation is a two- phase process , 
consisting of a T-cell receptor (TCR)-driven induction phase, where key transcription factors 
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are induced or activated, and a cytokine-driven polarization phase, in which expression of 
key factors is amplified and their differentiation is completed53. The lineage acquired depends 
upon the network of cytokines present and transcription factors expressed in the activated 
cells54. For each Th lineage differentiation, more than one cytokine is involved, and cytokines 
involved in differentiation of one lineage might suppress the differentiation of other subsets, 
thus driving the immune response in specific directions54.  
 
The main cytokines involved in T-cell differentiation, as well as transcription factors and 
cytokines specific for each subset are shown in figure 4. Interestingly, emerging data has 
suggested a certain degree of flexibility and plasticity of helper T cell polarization, indicating 
that induction of specific cytokine-producing and transcription factor T cell subsets is not a 
sign of terminally differentiation, but rather that the T cells remain responsive to stimuli from 
APCs, and can change their polarization47, 55. Whether these cells alter their cytokine-
producing potential and change their phenotype under physiological conditions in vivo is still 
uncertain47, 56, 57. 
 
1.2.3 CD4+ T CELL SUBSETS 
Th1 cells are competent effectors against intracellular bacterial and viral infections and 
promote cell mediated immune responses. Such cells secrete IFN-γ, IL-2, IL-10, TNF-α and 
TNF-β. Although Th1 cells are critical for the clearance of intracellular pathogens, 
exaggerated Th1 responses are associated with autoimmune diseases, including rheumatoid 
arthritis, multiple sclerosis and type 1 diabetes 
 
Th1 cells depend on the T-box transcription factor expressed in T cells (T-bet) together with 
signal transducer and activator of transcription (STAT) 4 during differentiation from naïve T 
cells. Furthermore, IL-12 and IFN-γ are important cytokines for the differentiation of Th1 
cells52. 
 
Th2 cells are critical for expelling extracellular parasites, and differentiate from naïve T cells 
in response to the cytokines thymic stromal lymphopoietin (TSLP), IL-4 and IL-2. 
 
The Th2 master regulatory transcription factor is GATA-3, which in combination with 
STAT6 induces differentiation of Th2 cells. In addition, aberrant Th2 cells are involved in 
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allergic responses and produce the classical Th2 cytokines IL-4, IL-13 and IL-5. These 
cytokines are pivotal for the induction and maintenance of allergic responses, i.e. IL-4 and 
IL-13 induce class switching and IgE-production in B cells and contribute to further 
differentiation of naïve T cells towards a Th2 phenotype. Furthermore, IL-5 is crucial for the 
activation of eosinophils, and IL-13 is involved in activation of mast cells and regulation of 
mucus production53,54,58. 
 
Th17 cells are effective in the defense against extracellular pathogens including bacteria and 
fungi. They are implicated in a broad spectrum of chronic inflammatory conditions and 
autoimmune diseases59 
 
Th17 cells differentiate from naïve T cells in the presence of IL-1β, IL-23, IL-6 and 
transforming growth factor β (TGF-β), and control extracellular bacteria and fungi through 
production of IL-17 and IL-22. Th17 cell differentiation depends on induction of the 
transcription factor RORγt together with STAT3.  
 
Th22-cells 
Th22 cells produce IL-22 and were initially described to be involved in the immunopathology 
of skin diseases. IL-22 was shown to be prominently expressed by T cells in skin 
inflammation60. 
 
Th22 cells are closely associated with Th17 cells, but represent a separate Th subset with 
distinct gene expression and functions. These cells produce IL-22 and IL-13, but not IL-17 or 
IFN-γ and express CCR4, CCR6 and CCR10. The transcription factor aryl hydrocarbon 
receptor (AhR) is required for IL-22 production in both Th17 and Th22-cells61, 62. Th22- cells 
are involved in tissue protection and wound healing at epithelial surfaces through induction 
of epithelial cell proliferation and antimicrobial peptides. In addition they may be engaged in 
the pathogenesis of autoimmune and allergic diseases63.  
 
Regulatory T cells (Tregs) 
Tregs can be generated in the thymus in the process of positive and negative selection, so-
called natural Tregs (nTregs), or in secondary lymphoid organs and tissues, so-called 
inducible Tregs (iTregs). 
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DCs play a major role in the induction of peripheral tolerance through generation of iTregs, 
in addition to induction of T-cell anergy and deletion64. iTregs are essential for maintaining 
peripheral tolerance, and execute suppressive functions by several different mechanisms, 
including modulation of the cytokine microenvironment, suppression of development of 
effector T cells, and suppression by targeting DCs65, 66. 
 
Tregs play a vital role in fine-tuning the balance between effector and tolerogenic responses. 
FoxP3 is a master regulator in Treg development, and is expressed in both nTregs and iTregs. 
iTregs express FoxP3 in response to defined tolerogenic stimuli such as TGF-β and retinoic 
acid (RA) in lymphoid tissues65.  
 
Other subsets of T cells with suppressive capacity have been described. One such subset is 
the inducible Type 1 regulatory (Tr1) cells, which produce the immunosuppressive cytokine 
IL-10. Distinct intracellular and surface markers and cytokine expression profile distinguish 
FoxP3+ Tregs and Tr1 cells from each other67. Interestingly studies in humans have 
demonstrated that the T cell response to allergens depends on a fine-tuned balance between 
allergen-specific effector cells and IL-10 producing Tr1 cells68, 69. 
  
Th9 cells 
IL-9 was initially viewed as a Th2 cell cytokine, however it is now recognized that a subset 
of CD4+ T cells preferentially produce IL-9, and is distinct from Th2 cells. Such cells depend 
on IL-2, TGF-β and IL-4 for their differentiation and survival, and their transcriptional 
regulation is controlled by PU.1 and IRF4, which synergistically regulate IL-9 production in 
Th9 cells52, 70. These cells facilitate immune responses against intestinal worms, but are also 
implicated in the immunopathology of allergy and autoimmunity71, 72. 
 
Tfh cells 
Follicular helper T (Tfh) cells provide help to B cells in lymphatic tissues, and are crucial for 
germinal center formation, affinity maturation and the development memory B cells. Their 
differentiation is regulated by IL-6, inducible costimulator (ICOS) and IL-12, and depend on 
the transcription factor Bcl673.  
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1.3 THE IMMUNOBIOLOGY OF DENDRITIC CELLS 
DCs are present throughout the body, and studies on their ontogeny and functions have 
revealed important roles during tissue homeostasis and disease, with the potential to induce 
both immunity and tolerance74.  
1.3.1 DENDRITIC CELL SUBSETS 
DC subsets and their functional specialization have been extensively studied in mouse 
models, whereas knowledge of human DC subsets is mainly derived from studies of skin and 
blood DCs.  
 
DCs comprise a heterogeneous group of cells, and can be defined according to expression of 
surface markers, their functional specialization, developmental origin, transcriptional 
regulation, patterns of migration or residence, and anatomical and micro-environmental 
localization75. 
 
In human blood, three main DC subsets have been identified based on their expression of 
surface markers; the CD1c+ (BDCA-1) DCs, CD141+ (BDCA-3) DCs and CD303+ (BDCA-
2+/ CD123+) plasmacytoid DCs (pDCs)76, 77. Traditionally these subsets can be broadly 
divided into two main groups; (i) myeloid (m)DCs that include CD1c+ DCs and CD141+ 
DCs, and (ii) plasmacytoid (p)DCs (CD123/303 + DCs)  
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Figure 5. Human dendritic cell subsets. Blood DCs are immature precursors of tissue-residing DCs. 
pDCs are mainly found in secondary lymphoid tissue, and blood-derived pDCs enter the lymphatic 
tissue through high endothelial venules. CD14 + monocytes may give rise to CD14+ tissue-residing 
DCs especially in case of inflammatory conditions in the tissue. Reprinted under the terms of the Creative 
Commons Attribution License (CC-BY); Haniffa et al. Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells 
with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells. Immunity 2012, 37(1): 60-73. © 2012 
Immunity published by Elsevier 
 
Circulating human blood DCs display an immature phenotype78, and serve as precursors for 
tissue-residing DCs (Figure 5).  
 
As previously described, there are two main subsets of monocytes in blood; CD14+ 
monocytes that may differentiate into inflammatory DCs during inflammatory responses in 
the tissue, and CD16+ monocytes with potential functions in the circulation (Figure 5)79. 
CD16+ monocytes were shown to crawl on the luminal side of the endothelium, sensing 
viruses and immune complexes via toll like receptor 7 (TLR7)- and 8, thus being involved in 
local surveillance of tissues80. 
 
In an inflammatory setting, cytokines and chemokines are produced at the site of 
inflammation, which attract CD14+ monocytes that migrate into the tissue and differentiate 
into inflammatory DCs. In several inflammatory conditions, such as atopic dermatitis, 
psoriasis, rheumatoid arthritis and tumor ascites, the presence of this subset of inflammatory 
Tissue
Blood
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DCs has been described. Also, trancriptomic analysis revealed that they likely derive from 
monocytes that differentiate at the site of inflammation34, 81.  
 
1.3.2 FUNCTIONAL SPECIALIZATION OF HUMAN DENDRITIC CELL SUBSETS 
The different DC subsets have unique surface receptor expression patterns and different 
functional capacities, thus arguing for a division of labor between the three main DC subsets 
in human mucosa79.  
 
CD141+ DCs uniquely express the lectin CLEC9A (DNGR-1)76, 35, and have been detected 
in several organs such as skin, lung and intestine, where they show a more mature phenotype 
compared to CLEC9A+/BDCA-3+ DCs in blood, indicating a more mature stage of 
differentiation76. Such cells were reported to produce high levels of IFN-α after recognition 
of synthetic dsRNA82 and high levels of IL-1283, thereby enabling Th1 polarization, which 
could be significant for a protective immune response against viral infections81. In the skin, 
resident CD141+ DCs were shown to produce IL-10 and induce regulatory T cells that 
suppress skin inflammation84,85. 
 
The initiation of CD8+ cytotoxic T cell responses is dependent on presentation of exogenous 
antigens on MHC class I molecules. This process is known as cross-presentation and is 
mainly utilized by DCs. In mice a subset of tissue-resident CD8+ DCs excel in cross-
presentation compared to other DC subsets86. CD141+ DCs have been proposed to be 
homologues to mouse CD8+ DCs and it was therefore suggested that they could be 
specialized in cross-presentation87. In line with this CD141+ DCs can cross-present antigens 
from dead cells better than other DC subtypes83, however they seem equally able to cross-
present soluble antigens when compared to other DCs88,87 Furthermore: the lectin CLEC9A, 
uniquely expressed on CD141+ DCs was shown to be required for cross-presentation of 
dead-cell associated antigens, and uptake of necrotic cells in mice89. This suggests a specific 
role for CLEC9A expressed on CD141+ DCs in uptake and presentation of necrotic cells. 
 
CD1c+ DCs comprise the largest population of DCs in blood, tissues and lymphoid organs. 
They express a wide range of TLRs, migrate to draining lymph nodes and stimulate naïve T 
cells efficiently76,79. This population of cells was shown to efficiently respond to 
Mycobacterium tubercolosis (M. tuberculosis) infection by inducing CD4+ T cell 
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proliferation90. Moreover CD1c+ DCs stimulated with Escheria coli (E-coli) suppressed T 
cell activation and produced high levels of the anti-inflammatory cytokine IL-10 and the 
regulatory molecule indoelamine 2,3 deoxygenase (IDO) suggesting the induction of a 
immunoregulatory CD1c+ DC phenotype upon E-coli infection91. CD1c+ DCs in tissue 
variably express the protein CD1a involved in presentation of lipids to T cells, making them 
candidates for processing and mounting immune responses against mycobacteria92. In the 
intestine CD1c+ DCs were shown to display an activated phenotype under homeostatic 
conditions, and produce IL-2393. 
 
In a study of DCs in human inflammatory fluids, a subset of CD1c+ DCs secreted Th17 cell-
polarizing cytokines and induced Th17 cells. Inflammatory CD1c+ DCs were shown to 
represent a distinct DC subset, enriched for gene signatures of monocyte-derived DCs. Thus 
under inflammatory conditions distinct subsets of monocyte derived CD1c+ DCs may 
mediate inflammation through activation of Th17-cells94. 
 
Plasmacytoid dendritic cells (pDCs) express CD123, CD45RA, CD303 (BDCA-2) and 
CD304 (BDCA-4), but lack expression of CD11c and CD14 which separate them from other 
DC subsets. They are crucial mediators of antiviral immunity and secrete large amounts of 
type 1 IFN in response to viruses79,95, which they sense with TLR9 and TLR7. They represent 
a rare subset of cells and are primarily found in the circulation (0.3-0.5 % of peripheral blood 
mononuclear cells (PBMCs)) and peripheral lymphoid organs during steady state96.  
 
Recent studies indicate that chronic pDC activation and secretion of type1 IFN in a non-
inflammatory setting may result in autoimmune diseases, with the strongest evidence found 
in diseases like systemic lupus erytheromatosus (SLE) and psoriasis97, 98. Furthermore; pDCs 
have been implicated in allergy and asthma99, antitumor immunity100 and responses to 
nonviral pathogens101, 102. Notably, depletion of pDCs in mice has been shown to cause 
sensitization and lung inflammation to a harmless antigen 103. Furthermore, human tonsillar 
pDCs induce allergen-specific FOXP3+ Tregs that can suppress effector T cells in vitro104 
suggesting that pDCs have tolerogenic functions in airway allergy105.  
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1.3.3 ONTOGENY OF DENDRITIC CELLS 
 
 
Figure 6. The distribution of major human dendritic cell subsets in blood, epithelial tissues and 
lymph nodes. Broken arrows indicate relationships that require further confirmation in humans. 
Human DCs can be generated either from granulocyte-macrophage progenitors (GMP) or multi-
lymphoid progenitors (MLP) both of which ultimately arise from hematopoietic stem cells (HSC). 
Classical monocytes, blood mDCs and pDCs are putative precursors of tissue and lymphoid DCs. 
Reprinted under the terms of the Creative Commons Attribution License (CC-BY); Collin M et al, Human dendritic cell 
subsets. Immunology 2013, 140(1): 22-30. ©2013 Immunology published by John Wiley & Sons Ltd 
 
Blood DC subsets are derived from hematopoietic stem cells, but the exact precursor-progeny 
relationship in human DCs is not clear. 
 
Classical monocytes, blood mDCs and pDCs are precursors of tissue and lymphoid DCs 
(Figure 6)75. In mice, DC subsets derive from a common DC precursor (CDP) that can 
differentiate into immature DCs in response to lineage restricted differentiation factors15, 16. 
Even though it is unknown whether committed DC precursors exist in humans it has been 
demonstrated that both granulocyte macrophage precursors (GMPs) and multilymphoid 
progenitors (MLPs) can give rise to DCs in vitro106 (Figure 6). 
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Important for the development of all DC subsets is the growth factor FMS-like tyrosine 
kinase 3 ligand (Flt3L) and its receptor Flt3, underscored by the fact that mice lacking Flt3L 
have deficient hematopoiesis affecting hematopoietic stem cells and DCs107. Furthermore; the 
injection of Flt3L into humans dramatically increased the number of all blood DC subsets108 
and several studies have shown that the number of DCs and level of Flt3L are inversely 
correlated107,109. 
 
Recently, three genetically defined syndromes of DC deficiency were described in humans. 
One of them, caused by a mutation in GATA2, which encodes a transcription factor involved 
in the homeostasis of hematopoietic stem cells, resulted in complete loss of MLPs, in addition 
to DC, monocyte, B and NK cell (DCML) deficiency. This mutation also resulted in 
massively elevated serum levels of Flt3L in line with the notion that Flt3L is a key protein in 
the development and maintenance of DCs110. In another set of patients, a specific autosomal 
dominant sporadic mutation (T80A) of the transcriptional regulator IRF 8 resulted in 
selective reduction in the number of CD1c+ DCs, but not CD141+ DCs or pDCs, implicating 
an important role for IRF8 during CD1c+ DC development. This mutation was linked to 
increased susceptibility to mycobacterial infection111, in line with the reports that CD1c+ DCs 
have important functions in the immune response towards mycobacterial infections90. In one 
patient an autosomal recessive mutation (K108E) of IRF8 resulted in complete loss of 
peripheral blood mDCs, pDCs and monocytes. 
 
Human DC subsets have been proposed to depend on unique and specific master transcription 
factors. The transcription factor E2-2 is specifically required for pDC development, and its 
expression is crucial to maintain the pDC phenotype102, 112, 113. CD141+ DCs depend on the 
transcription factor Batf3 for their ontogeny, as development of CD141+ DCs was selectively 
prevented by knockdown of Batf3 in vitro114. Furthermore, IRF-4 has been demonstrated to 
stabilize the lineage commitment of CD1c+ DCs35, 115. 
Recently a zinc finger transcription factor, zDC (zbtb46), was found to be specifically 
expressed by mDCs and committed mDC precursors in mice, but not by monocytes, pDCs or 
other immune cell populations, supporting the notion that mDCs constitute a unique immune 
cell lineage116, 117. In our hands this transcription factor was unable to differentiate human 
macrophages and DCs (Melum, unpublished results) which might represent differences 
between species. 
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Langerhans cells (LCs) expressing CD1a is a notable exception to the rule that DCs are 
derived from blood and bone marrow precursors. Such cells are maintained in the epidermis 
of the skin independently of circulating precursors118 and animal studies have shown that LCs 
are derived from yolk sac cells seeded during the embryonic period. Notably, after a human 
limb transplantation LCs of donor origin have been observed in the skin of the host for up to 
10 years119 120.  
 
1.4 DENDRITIC CELLS DURING IMMUNE HOMEOSTASIS 
The maintenance of balance between tolerance and immunity is a complex process that can 
easily be disturbed. In addition to recognition of danger and thus initiation of immune 
responses, DCs have a central role in keeping the immune system “at ease” when no danger 
is present in the tissue. To accomplish this task DCs continuously process and present self- 
and non-pathogenic antigens to T cells. In this context, effector T cells are not induced to 
proliferate, but rather, the differentiation of immunosuppressive Tregs producing 
immunosuppressive cytokines is favored50.  
 
DCs continuously interact with T cells to induce antigen-specific refractoriness or tolerance 
in organized lymphoid tissue and in the periphery74,121. The maintenance of self- tolerance 
and unresponsiveness by DCs is influenced by several factors, including the activation status 
and type of DCs, and the local cytokine milieu75. Thus, the tissue environment is crucial for 
maintenance of immune homeostasis, and depends to a large extent on cytokines produced 
continuously by epithelial and stromal cells in the tissue. During non-inflammatory 
conditions, epithelial cells produce the immune-modulating cytokines TGF-β and RA, shown 
to be crucial for the DC-mediated induction of Tregs in mice122, 123. A subset of intestinal 
DCs in mice was shown to activate the latent form of TGF-β and thereby inducing Foxp3+ 
Tregs122.  
 
In addition, DC characteristics like their maturation status or expression of certain receptors 
are involved in maintenance of immune homeostasis. Antigen presentation by immature DCs 
typically results in immune tolerance because of deficiency of co-stimulatory molecules64,74, 
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whereas activated mature antigen-bearing DCs may initiate the differentiation of antigen-
specific effector T-cells as previously described.  
 
Exposure to various anti-inflammatory cytokines and immunosuppressive agents can shape 
DCs to a tolerogenic state. For example DCs generated in vitro, in the presence of anti-
inflammatory factors such as vitamin A, prostaglandin E2 (PGE2), IDO, IL-10 and TGF-β 
exhibit tolerogenic functions64. The enzyme IDO is expressed by DCs, and is a negative 
immune regulator that depletes tryptophan by catalyzation of the first step in tryptophan 
catabolism. Depletion of tryptophan modulates the activity of the immune system and 
mediates Treg proliferation and activation, inhibition of effector T cell responses and 
decreased cytotoxic T-cell activity124.  
 
Furthermore, receptors expressed on DCs may mediate tolerogenic responses. One such 
receptor is AXL, a member of the TAM (TYRO3, AXL and MER) receptor tyrosine kinase 
family, which inhibits inflammation in DCs and macrophages and promotes phagocytosis of 
apoptotic cells125. AXL expressed on DCs mediates increased uptake of apoptotic cells and 
blocks proinflammatory cytokine production upon TLR stimulation126. This is mediated 
through induction of suppressors of cytokine signaling (SOCS) molecules, which inhibit both 
TLR and cytokine receptor cascades, thereby attenuating the inflammatory response125. 
 
In summary, DCs are important immune modulators and mediate immune homeostasis 
through various mechanisms. 
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1.5 AIRWAY ALLERGY AND ALLERGIC RHINITIS 
The prevalence of allergic diseases worldwide is rising dramatically in both developed and 
developing countries. Allergic rhinitis is becoming increasingly common, affecting more than 
30 % of the population in the western society. A high proportion of this increase is occurring 
in young individuals, thus the burden of allergic disease is expected to increase even more127. 
Allergic rhinitis is most often a chronic disease which can impose major impact in quality of 
life for the patients, and also inflict a significant burden on health care resources. 
Furthermore, allergic rhinitis is a known risk factor for asthma and effective treatment of 
allergic rhinitis has a preventive effect in the development of asthma128. 
 
1.5.1 IMMUNOPATHOLOGY OF ALLERGIC RHINITIS 
An allergic reaction occurs when normally harmless substances trigger an immune response. 
Key players in this process are immune cells (e.g. mast cells, DCs, T cells, and B cells) and 
stromal cells. The process has two phases; the sensitization phase where genetically 
susceptible individuals react towards a harmless substance (allergen) by producing antigen-
specific IgE. Secondly, in the allergic effector phase the allergen triggers an immune reaction 
which leads to an allergic inflammation in the tissue129. Mast cells armed with allergen-
specific IgE may induce a rapid allergic response upon binding to the allergen and subsequent 
cross-linking of IgE-FcέRI complexes. 
 
However, it is important to emphasize that not all sensitized individuals develop an allergic 
inflammation130 and the question why only some sensitized people develop allergy is still 
unresolved. Several factors might be important, such as differences in the local 
microenvironment including the stromal cell compartment. For instance in the upper airway 
mucosa of allergic rhinitis individuals an increased local production of IgE from resident B 
cells has been shown131, 132. In addition, local class switching to IgE may take place in the 
nasal mucosa of allergic rhinitis patients but not in healthy individuals133. Thus, higher IgE 
present at effector sites in allergic individuals may be a factor that contributes to development 
from sensitization to allergic disease. In addition, clinical trials of allergen specific 
immunotherapy (SIT) have demonstrated that the induction of a tolerant state in peripheral T 
cells represents a key factor in the development of healthy immune responses towards 
allergens. Thus the balance between effector Th2 and regulatory T cells might represent 
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important differences in the immune response towards allergens in healthy and atopic 
individuals134.  
 
Furthermore, genetic regions have been linked to atopy and allergy135. Genome-wide 
association studies (GWAS) allow for the discovery of novel genes and pathways involved in 
disease pathogenesis, and nearly 100 asthma and genes/loci in addition to multiple genes/ loci 
for allergic rhinitis have been identified by GWAS studies136 A large meta analysis of GWAS 
in ethnically diverse asthmatic patients showed that only 5 genes reached statistic 
significance among which 3 of them are related to cytokines secreted from stromal cells and 
epithelium; TSLP, IL-33, and its receptor ST2137. 
 
However a rapid increase in allergy over the last decades implies that genetic factors can be 
only partially responsible, favoring a significant contribution from environmental factors136. 
It has become clear that environmental conditions, for instance microbes or air pollution 
present during allergen exposure, may cause tissue damage and interfere with the normal 
sensitization process138. The hygiene hypothesis suggests that decreased exposure to 
pathogens during infancy leads to defective maturation of the immune system and results in 
increased risk of developing allergies139. Furthermore, asymptomatic subjects may be 
sensitized to only one allergen (monosensitization), as opposed to patients who more often 
may be sensitized to several different substances (polysensitization)140.  
 
To further understand the processes that lead to development of allergic inflammation, it is 
important to study the key players involved in allergic immune responses. Understanding the 
functions of DCs in these immunological processes may be a key for novel therapeutic 
approaches in allergic disease. 
 
  
23 
1.5.2 MECHANISMS IN UPPER AIRWAY ALLERGY  
 
Allergen sensitization phase of allergic rhinitis 
 
 
Figure 7: The allergic sensitization phase. Allergens in the airway mucosa can be sampled by DCs, 
transported to regional lymph nodes and presented to naïve T cells. Under certain conditions naïve T 
cells acquire the characteristics of Th2 cells, and activate B cells to undergo immunoglobulin class-
switch recombination, such that the antibody of the IgE class is produced. IgE is then distributed 
systemically and binds to the FcεRI on tissue-resident mast cells, thereby sensitizing them to respond 
when the host is later re-exposed to the allergen.  
Reprinted with permission from Nature publication: Galli SJ, Tsai M, Piliponsky AM. The development of 
allergic inflammation. Nature 2008, 454(7203): 445-454. ©2008 
 
Allergens are sampled by DCs in the airway lumen, processed and transported to a regional 
lymph node (Figure 7). In the presence of the cytokine IL-4, DCs differentiate naïve T cells 
into Th2 cells, producing IL4 and IL13. These cytokines contribute to activation and Ig class 
switch in B cells, a process were the gene segments that encode the Ig heavy chain are 
rearranged such that antibody of the IgE class is produced. Allergen specific IgE is 
distributed systemically, and after gaining access to the mucosa they bind to the high-affinity 
receptor for IgE (FcέRI) on tissue-resident mast cells, thereby sensitizing these to respond 
when the host is re-exposed to the allergen129. 
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The effector phase of allergic rhinitis 
The effector phase of an allergic reaction is divided into an immediate response and a late-
phase response. 
 
 
Figure 8. The immediate effector phase of allergen induced airway inflammation 
Activation of IgE armed mast cells through FcέRI aggregation results in rapidly secreted preformed 
mediators and increased synthesis of cytokines, chemokines and growth factors. The rapidly secreted 
mediators result in bronchoconstriction, vasodilation, increased vascular permeability and increased 
mucus production. Mast cells also contribute to the transition to late-phase reaction by promoting 
influx of inflammatory leukocytes.  
Reprinted by permission from Nature publication; Galli SJ, Tsai M, Piliponsky AM. The development of allergic 
inflammation. Nature 2008, 454(7203): 445-454. ©2008 
 
The immediate reaction in allergic rhinitis 
In sensitized individuals, mast cells armed with allergen specific IgE reside in the mucosa. 
Encounter with allergen may lead to cross-linking of FcεRI and release of a number of 
inflammatory mediators like vasoactive amines, lipid mediators and chemokines that create 
the immediate phase of the allergic reaction (Figure 8). This occurs within an hour after the 
initial exposure, and brings on the classical symptoms seen during the acute phase reaction in 
allergic rhinitis; sneeze, itchy and red eyes and coughing, due to vasodilation of blood 
vessels, leucocyte recruitment, increased mucus production by goblet cells and airway 
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bronchoconstriction. Mast cell activation also leads to de novo generation of mediators, 
contributing to the ongoing inflammatory response. 
 
The late phase response 
4-12 hours after the initial encounter with allergen, memory Th2 cells, DCs, as well as other 
members of the immune cell family will contribute to an ongoing inflammatory response129, 
141. This may lead to chronic allergic inflammation, tissue damage and consequently airway 
remodeling, leaving permanent damage to the tissue, especially if the lower airways are 
involved129.  
 
1.5.3 DENDRITIC CELLS IN UPPER AIRWAY ALLERGY 
DCs have been implicated as essential initiators of allergic responses, both in the sensitization 
phase and during an ongoing allergic inflammation142. Studies in mice demonstrated that DCs 
are required for the initiation of allergic responses143 Furthermore, early studies of grass 
pollen allergic individuals showed accumulation of DCs in the upper airways during pollen 
season144. In line with this it was demonstrated that DCs have an essential role in 
experimental allergic rhinitis145.  
 
There is compelling evidence to show that the tissue environment the DCs reside in upon 
allergen encounter is essential for the outcome of these processes146, 147, 148. Interactions of 
allergens with epithelial cells and various pro-inflammatory substances promote disruption of 
epithelial integrity and production of Th2-skewing cytokines like TSLP, IL-33 and IL-25 by 
epithelial cells149. By integrating signals from the environment, DCs activate naïve T cells to 
become Th2 cells, producing the hallmark Th2-cytokines responsible for induction of the 
allergic inflammatory response (Figure 9). Thus, DCs are initiators of the allergic cascade, 
directing the process of sensitization and the effector phase of an allergic inflammation. 
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Figure 9. DCs integrate signals from the airway epithelium to mount Th2-responses 
 
Monocytes and macrophages in allergic rhinitis 
Antigen presenting cells (APCs) other than DCs might contribute to the immunopathology of 
allergic rhinitis.  
 
Monocytes may serve as precursors for inflammatory DCs, and animal studies have shown 
that monocyte-derived DCs (moDCs) are necessary and sufficient for induction of Th2 
immunity and features of asthma150, 151. MoDCs generated Th2 responses in the tissue by 
chemokine production and antigen presentation, but were dependent on high doses of antigen 
to induce Th2-inflammatory responses. Also, DCs were needed to induce Th2 cell-mediated 
immunity in the lymph node, suggesting a division of labor between moDCs and DCs in an 
allergic inflammatory response150. 
 
As previously described, alternatively activated M2 macrophages may be effector cells in 
allergic inflammatory responses. Interestingly, a study in mice reported that imbalance in the 
gut microbiota altered the macrophage phenotype towards M2 via PGE2, resulting in 
enhancement of allergic airway inflammation152. The role of monocyte-derived cell subsets in 
human allergic airway responses is poorly characterized. 
 
TSLP and immunoregulation 
TSLP is a cytokine that plays essential roles in allergic inflammatory disorders in the skin 
and airways. TSLP belongs to the IL-7 cytokine family, and was originally shown to promote 
B-cell growth and development153, but was later demonstrated to be crucial for the induction 
27 
of Th2 responses by driving DC maturation154, 155. Co-culture of TSLP-stimulated DCs with 
naïve allogeneic T-cells results in the generation of inflammatory Th2 cells that produce IL-4, 
IL-5, IL-13 and TNF-α156. This Th2-driving phenotype was shown to depend on upregulation 
of the costimulatory molecule OX40L on TSLP-treated DCs in addition to lack of IL-12155.  
 
TSLP signaling is mediated by a heterodimer composed of the IL-7 receptor α-chain, and 
TSLP receptor (TSLPR). Activation of TSLPR by TSLP leads to activation of nuclear factor 
κB (NfκB) and phosphorylation and activation of STAT5 and STAT 6157, with the 
subsequent upregulation of OX40L and production of chemokines necessary for the 
recruitment of Th2 cells158.  
 
TSLP is produced by epithelial cells, keratinocytes and stromal cells, and induction of TSLP 
has been demonstrated in several allergic diseases including atopic dermatitis, allergic rhinitis 
and asthma156, 159. In vitro studies of human keratinocytes and bronchial epithelial cells 
demonstrated that Th2 cytokines, rhinovirus infection, TLR3 ligands and allergens with 
protease activity are potent inducers of TSLP160, 161.  
 
In contrast to its role in the development of allergic disorders, TSLP was reported to be 
constitutively expressed by human intestinal epithelial cells (IECs) implying a role in 
maintenance of immune homeostasis at this site. In fact, TSLP produced by IECs conditioned 
DCs to become non-inflammatory, secreting less IL-12p40, and driving the generation of 
FoxP3+ Tregs162. In the setting of TSLP-related homeostatic maintenance in the gut, TSLP 
was produced by DCs, thus controlling Th17 and Treg cell development163.  
 
Recent work highlighted the previous unrecognized fact that TSLP consists of at least two 
splice variants that have different functions; the short form TSLP, being constitutively 
expressed and implicated in immune homeostasis, and the long form TSLP which is the only 
variant that encodes a protein that has been shown to activate TSLPR, and thus associated 
with allergic inflammation164, 165, 166. These findings might explain the reported presence of 
TSLP under both inflammatory and homeostatic conditions, and highlight the necessity of 
analyzing the two isoforms separately. 
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In conclusion, DCs have been shown to play important roles in maintenance of immune 
homeostasis and initiation of allergic responses, however relatively little is known about the 
heterogeneity and functional characteristics of human DC subsets. 
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2. AIMS OF THE STUDY 
The main focus of this thesis is human DCs and their functional properties during steady state 
and allergic airway inflammation. 
We aimed to identify mechanisms involved in immune homeostasis and allergic responses in 
the human airway mucosa. 
To this end our objectives were to 
 Define the DC compartment in the upper airway mucosa at steady-state. (paper I and 
III) 
 Assess mechanisms by which airway mucosal DCs promote tolerance at steady state. 
(paperIII) 
 Determine phenotypes and functions of DCs in human upper airway mucosa during 
airway allergy (paper I) 
 Explore the feasibility of performing system biology studies on cell populations 
isolated from human upper airway biopsies during experimentally induced allergic 
rhinitis (paper II) 
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3. MATERIALS AND METHODS 
This section discusses advantages and limitations of the main methods included in this thesis. 
A detailed description of material and methods can be found in the methods sections of the 
individual manuscripts.  
 
3.1 IN VIVO ALLERGEN CHALLENGE (Paper I and II) 
For study I and II allergic volunteers with a typical history of pollen-induced upper airway 
allergy and positive skin-prick test or allergen-specific IgE in serum to the relevant pollen 
were included. In study I, healthy volunteers were included as controls. All subjects were 
non-smoking, had no nasal polyps, nasal deformities or recent nasal surgery.  
Participants were challenged with relevant allergen for seven days, and biopsies were 
obtained from the lower edge of the inferior turbinate at day 0 and 7 (study I and II a), and at 
day 0-3 and 7 (study II b) (Figure 10). The challenge was performed outside of pollen season 
when the patients had no symptoms.  
 
In this model the dose of allergen is standardized, in contrast to the allergy season where the 
allergen dose is highly variable.  
 
 
Figure 10. Outline of the experimental setup in article I and II 
 
The main advantage of this experimental model for allergic rhinitis is that it enables the study 
of factors affecting the immune system during allergic inflammation in vivo, thus allowing 
for studies of the immune cells in their natural habitat. Moreover, it is unique because it is 
possible to follow the initiation phase of an inflammatory reaction in humans and the 
dynamics over time. 
 
Biopsies
Nasal challenge
Day 0 Day 3 Day 7
31 
For phenotyping of mucosal DCs (study I and III), and in vitro studies on blood DCs in 
(study I and III) we used blood-derived primary DCs, nasal mucosal biopsies obtained during 
septum deviation surgery in otherwise healthy donors, as well as macroscopically healthy 
small intestinal tissue obtained during pancreas cancer surgery.  
 
3.2 QUANTITATIVE REAL-TIME PCR AND CULTURE OF HUMAN BIOPSIES 
For the study of TSLP induction in human nasal mucosa we measured mRNA expression, 
since we wanted to differentiate between the long and short form of TLSP. Currently no 
antibodies can differentiate between the two different TSLP-isoforms making it difficult to 
investigate the induction of long-form TSLP protein in our in-vivo challenged material.  
 
Nasal mucosal biopsies were cultured 4 hours with or without the cytokines IL-4, IL-13 and 
TNF-α, and the biopsies were minced in TRI-reagent prior to RNA purification and cDNA 
synthesis. The quantity and purity of the RNA was assessed with a NanoDrop 
spectrophotometer, and the RNA integrity was analyzed on an Agilent 2100 Bioanalyzer.  
  
3.3 ANALYSIS OF MICROARRAY DATA 
Microarray analysis is a transcriptional profiling method that enables the study of the 
expression levels of thousands of genes simultaneously, usually by pairwise comparison (i.e. 
healthy vs. pathological conditions). A DNA microarray is a collection of microscopic DNA 
spots attached to a solid surface. Each spot contains multiple identical unique strands of 
DNA, known as a probe. Each spot represents one gene, and is a short sequence of a gene 
transcript that can base pair with a complementary DNA strand in the process of 
hybridization.  
 
In paper II and III, we made use of transcriptional profiling to discover genes or gene 
interactions central to the allergic disease process (paper II), and genes differentially 
expressed in circulating and upper airway DCs (paper III).  
 
In paper II, defined cell subsets from nasal mucosal biopsies were sorted based on expression 
of surface markers (CD4+ T cells and CD45+ HLA-DR+ APCs). Purity check after sorting 
revealed high purity within each population (>95%), however analyses of data from the T cell 
population uncovered probable contamination with non- T cells, most likely stromal cells 
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since they comprise a relatively large proportion of cells within the biopsy, and even small 
amounts of stromal cells will have an impact on the end result. To overcome this challenge 
we used a filter created based on allergen challenged T cells, ensuring the genes analysed was 
relevant for the T cell population. One could argue that this procedure would miss out on 
novel findings since the filter will narrow down the number of genes available, however 
novel genes within the T cell population would still be possible to uncover. 
 
In the same study, we used immunohistochemistry to validate a selection of the upregulated 
genes on a protein level. This was done on a separate study population to further strengthen 
the validity in our findings. Due to practical limitations it was not feasible to perform 
immunohistochemistry on nasal biopsies in parallel with gene expression analysis as the 
amount of tissue one can sample during allergen challenge from each donor is limited.  
 
3.4 IMMUNOFLUORESCENCE STAINING 
The principle of immunofluorescence staining is that primary antibodies of different Ig 
subclasses or species can be detected with secondary fluorescent labeled antibody, specific 
for the relevant Ig. 
 
In paper I and II two- or three-color immunofluorescence staining was performed on frozen 
sections from biopsies taken pre- and post allergen challenge. As a control for unspecific 
binding, parallel staining experiments were performed with concentration-matched irrelevant 
isotype control. To determine cell densities, the cells of interest were counted in a 
fluorescence microscope by superimposing a grid parallel to the basement membrane of the 
surface epithelium.  
 
3.5 FLOW CYTOMETRY  
Flow cytometry was used for phenotypic characterization of cells (paper I and III), detection 
of intracellular signaling by means of phosphoflow assays (paper I), measurement of cytokine 
concentrations in supernatants after cell culture experiments by means of cytometric bead 
arrays (CBAS) (paper I),sorting of cells from tissue biopsies (paper II) and for cytokine 
production (paper I and III). 
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Flow cytometry allows for the study of large amounts of cells and several different markers 
in the same sample. It is a sensitive technique that makes it possible to detect relatively rare 
cell subsets, such as APCs and T cells from small mucosal biopsies.  
 
To avoid misleading results, caution must be made to avoid improper gating, and “bleed 
through” signals from overlapping fluorochromes. This can be avoided by running 
compensation controls to reveal overlapping signals. 
 
Phosphorylation of proteins is a crucial post-translational modification that regulates a broad 
range of cellular activities such as cell differentiation and metabolism. As previously 
described, phosphorylation of STAT5, an intracellular signaling molecule, has been shown to 
be an event downstream of TSLPR activation. To detect TSLPR activation in DCs, we made 
use of a phospho-STAT5-specific antibody to detect intracellular signaling upon TSLP 
activation of DCs. This makes it possible to perform single cell analysis on a defined 
population of cells. Because of the transient nature of intracellular signaling events, fixation 
techniques used for phospho-protein analysis must be rapid and efficient to prevent 
dephosphorylation. To find the optimal time for stimulation and fixation/permeabilization 
procedure, experiments with STAT5 phosphorylation upon IL-4 stimulation in peripheral 
blood mononuclear cells (PBMCs) were performed.  
 
3.6 STATISTICAL ANALYSIS 
During analysis of data it’s important to make use of the proper statistical methods to be sure 
to end up with reliable results. Because of small number of samples in some of the 
experiments, normal distribution could not be expected and non-parametric methods were 
applied. Wilcoxon signed rank test was used for paired data, and differences between groups 
were determined by Mann Whitney U test. For correlation analysis Spearman correlation test 
was used. 2-way ANOVA was used for differences between groups where the response was 
affected by two factors. To perform the statistical tests, Graph pad Prism 5.0 was used. A p-
value of < 0.05 was considered significant.  
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4. SUMMARY OF RESULTS 
 
4.1 PAPER I: A THYMIC STROMAL LYMPHOPOIETIN–RESPONSIVE DENDRITIC CELL SUBSET 
MEDIATES ALLERGIC RESPONSES IN THE UPPER AIRWAY MUCOSA 
In this paper the role of DCs in human allergic rhinitis was studied. A distinct subset of 
CD1c+ DCs was shown to express the receptor for TSLP, a cytokine involved in aggravation 
of Th2 responses and in particular allergic airway disease. The number of these cells 
increased in the upper airways of allergic individuals during an allergic inflammation. Upon 
stimulation with TSLP these cells obtained enhanced capacity for activation of allergen-
specific memory Th2 cells and up regulated CCR7, indicating an increased capacity for 
lymph node migration. The CCR7- effect was abrogated by the Th2 cytokines IL-4 and IL-
13, suggesting that during an allergic inflammation, DCs are retained in the tissue to further 
aggravate the allergic response by activating memory Th2 cells residing in the tissue. 
 
Conclusion of the study: A subset of human airway DCs is involved in the induction of 
allergic airway inflammation through their responsiveness to TSLP. TSLP activation triggers 
CCR-7 dependent migration to draining lymph nodes and enhances their capacity to initiate 
Th2 responses. 
 
4.2 PAPER II: IDENTIFICATION OF GENE NETWORKS ACTIVATED DURING EXPERIMENTAL 
ALLERGIC RHINITIS IN HUMANS 
In this study we describe gene networks activated during experimental rhinitis in humans. By 
taking a system biology approach we could perform comprehensive analysis of gene 
networks relevant to the allergic immune response in the tissue. Allergic rhinitis is a complex 
immunological disease involving various cell subsets including immune cells and stromal 
cells, making it beneficial and necessary to study whole system biology as opposed to limited 
groups of selected biomarkers. 
 
We aimed to construct a cell-to-cell co-expression network of genes to identify cellular 
relationships during the inflammatory reaction. In a challenge model of allergic rhinitis, 
APCs and T cells were sorted from the tissue after allergen challenge in allergic subjects. 
Bioinformatic analyses revealed T cells expressing a mixed Th2/ regulatory phenotype, with 
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evidence of recent migration into the tissue. APCs displayed increased capacity for antigen 
presentation in addition to production of Th2 related cytokines. Central in gene expression in 
DCs were IL-4/ IL-13 inducible genes. 
 
Conclusion of the study: It is possible to perform gene network analysis on various specific 
cell populations from small biopsies. Furthermore, our findings suggest that CD45+HLA-
DR+ cells (which include monocyte-derived cells, macrophages and DCs) are producers of 
Th2-associated chemokines, important for the recruitment of Th2 cells and eosinophils. 
4.3 PAPER III: STEADY-STATE MUCOSAL CD1A+ DENDRITIC CELLS DISPLAY 
IMMUNOREGULATORY PROPERTIES  
In this paper we identify a subset of CD1c+ DCs expressing CD1a in human upper airways 
and small intestinal mucosa that display signs of immune regulatory functions, potentially 
involved in maintenance of immune homeostasis. Blood-derived CD1c+ DCs displayed 
similar characteristics when incubated with TGF-β. TGF-β-stimulated CD1c+DCs upregulate 
CD1a, express AXL, a receptor involved in maintenance of immune regulation, and produce 
low amount of TNF-α in response to activation with LPS. 
 
Conclusion of study: A subset of upper airway and small intestinal DCs display properties 
suggesting involvement in immune regulation. Thus, CD1c+ DCs coexpressing CD1a may 
represent human tolerogenic DCs. 
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5. RESULTS AND GENERAL DISCUSSION 
DCs are important for the generation of effective immune responses and maintenance of 
immune homeostasis. Allergic asthma and rhinitis are T cell-mediated diseases, where 
susceptible individuals develop a Th2-dominated inflammatory immune response against 
allergens167. To initiate these responses DCs are both sufficient and necessary, as 
demonstrated in mice where DC depletion abolished the initiation of Th2 responses against 
house dust mites151.  
 
Early studies showed that in allergic rhinitis there is an increase of HLA-DR+ cells, thus 
indicating a role for APCs in the effector phase of allergic rhinitis168. Also, during 
homeostatic conditions, a subset of intestinal mouse CD103+ DCs has been shown to be 
important by promoting differentiation of FoxP3+ regulatory T cells from naïve T cells 
through mechanisms involving TGF-β and the metabolite RA123, suggesting that this subset 
represent a tolerogenic subset in mice. The possibility that a similar tolerogenic subset exists 
in humans remains to be explored.  
 
In this thesis, we provide evidence that CD1c+ DCs in human upper airways play a role in 
allergic inflammatory reactions and display tolerogenic properties during immune 
homeostasis. 
 
CD1c+ DCs are central in human allergic rhinitis 
The basis for study I was emerging data revealing that the pathogenesis of allergic 
inflammation is a combined result of barrier dysfunction and loss of immunological tolerance 
to harmless antigens. Thus damaged epithelium, caused by genetic and/ or environmental 
factors, leads to the production of various proteins (eg IL-33, CD25 and TSLP) that can 
activate immune cells to initiate allergic responses169. In particular; the epithelial cytokine 
TSLP has been shown to promote Th2 responses and play a crucial role in the development 
of allergic inflammations through activation of DCs170 171. However, whether DCs in the 
human upper airways respond to TSLP had not been investigated.  
 
Mucosal DCs may be involved both in the sensitization and the allergic effector phase of an 
allergic inflammatory response. As previously described, the sensitization phase is initiated 
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by DCs, sampling antigens in the periphery and subsequently migrating to the draining lymph 
nodes for presentation and activation of naïve T cells172. In addition, allergen-specific 
memory T cells reside in the airway mucosa and may be activated locally when inhaled 
allergens are presented by DCs in situ. Furthermore, during the effector phase of an allergic 
reaction there might be a continued sensitization of naïve T cells to further enhance the 
inflammatory process, thus DCs may be involved in allergen-triggering of recall responses, 
making them attractive targets for allergy treatment173.  
 
We found that expression of the receptor for TSLP was almost confined to a subset of CD1c+ 
DCs, being expressed by the majority of these cells (paper I).  
 
Furthermore, TSLP-stimulated CD1c+ DCs upregulated CD1a, a molecule involved in lipid 
presentation to T cells, and had an increased capacity to activate memory Th2-cells 
supporting the notion that DCs are involved in the recall phase of the allergic reaction. Plant 
pollen act as vehicles for foreign protein antigens and are important initiators of allergic 
responses through activation of DCs. In addition, plant pollen contain lipids that are 
recognized by human CD1 restricted T cells174. Thus the observed increased expression of 
CD1a might contribute to increased T cell recognition of lipids from pollen, thus 
exacerbating the allergic response.  
 
In addition, TSLP-stimulated DCs upregulate CCR7, thus making them capable of lymph 
node migration. However, the Th2 cytokines IL-4 and IL-13 abrogate the TSLP-mediated 
upregulation of CCR7, indicating that during an allergic inflammatory reaction in the 
mucosa, DCs are retained in the tissue to further exacerbate the allergic inflammatory 
response locally. This was reflected in the in vivo allergen challenge model where 
CD1c+CD1a+ DCs accumulated in the tissue, potentially caused by both increased 
recruitment of DCs from blood and decreased migration from the tissue due to IL-4/IL-13 
dependent down regulation of CCR7. This is in line with previous reports showing that 
CD1a+ DCs are increased in the nasal mucosa of allergics during the grass pollen season173. 
A recent study reported that in mice, aeroallergen challenge promotes DC proliferation in the 
airways, thus leading to accumulation of DCs in the tissue175, however in our allergen 
challenge model in human upper airways, staining for Ki-67 revealed no proliferating cells 
within the HLA-DR+ cell population (Melum, unpublished data).  
38 
 
Upregulation of CCR7 by TSLP might be important in the sensitization phase, as well as in 
the early effector phase when DCs migrate to the lymph nodes to recruit memory T cells. On 
the other hand, downregulation of CCR7 by IL-4 and IL-13 might also serve to dampen the 
inflammatory reaction since reduced migration of DCs will reduce the activation and homing 
of new allergen-reactive T cells to the site of inflammation, and furthermore reduce the 
possibility for a systemic inflammatory reaction. In the upper airway mucosa; mast cells 
armed with allergen-specific IgE might be an early source of IL-4 and IL-13, thus initiating 
TSLP production by epithelial cells after encounter with the allergen176, 177. Allergen 
proteases might also induce TSLP secretion from epithelial cells directly161.  
 
Different factors like allergens with protease activity and the Th2 cytokines IL4 and IL13 
have been shown to trigger TSLP production in epithelial cells161, 160; however few studies 
have taken into account that TSLP consists of at least two splice variants, one being involved 
in immune homeostasis, whereas the other activates the TSLPr and induces Th2 responses164, 
165. To investigate if the long form of TSLP, associated with allergic inflammation is 
produced by cells in the nasal mucosa, we cultured nasal mucosal biopsies with IL-4 and IL-
13 and found induction of long from TSLP after 4 hours culture. This indicated that TSLP is 
involved in the early phase of the recall response of an allergic reaction, priming DCs to 
activate resident memory Th2 cells.  
 
TSLP has been shown to play a role in the immunopathology of several different disorders178, 
179, 180; however without any discrimination between isoform specific subtypes one cannot be 
sure which of the two functionally different forms was detected during examination. This 
raises the important question of whether the short form TSLP, which was shown to have 
antimicrobial and homeostatic properties165 is upregulated in various inflammatory 
conditions. Future investigations of TSLP should include isotype-specific primers or 
antibodies to seek answers to these questions. 
 
Recently, the first clinical trial of TSLP blockade in allergic asthma showed promising results 
with evidence for attenuation of measures of allergen-induced early and late allergic 
asthmatic responses. Following allergen bronchoprovocation, patients with allergic asthma 
pretreated with anti-TSLP displayed lower blood and airway eosinophil counts and reduced 
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fraction of exhaled nitric oxide as compared to the control group181. The biological 
mechanisms on how blocking of TSLP serves to ameliorate both the early and late phase of 
asthmatic responses is not clear182, but based on our findings one can speculate that it 
involves reduced activation of DCs, thus dampening the allergic response.  
 
CD4+ T cells and APCs actively participate and interact in the chronic phase of allergic 
airway inflammation 
A systems biology approach to investigate the immunopathology during the allergic 
inflammatory response may prove beneficial. To this end our goal was to explore the 
possibility of using an in vivo challenge method to study networks of gene expression 
induced in upper airway APCs and T cells during pollen induced allergic rhinitis in allergic 
individuals.  
 
The allergic inflammatory upper airway mucosa showed signs of recently recruited activated 
Th2 cells and Foxp3 regulatory T cells (study II), in line with the notion that activation of 
effector T cells is accompanied by a set of regulatory T cells to dampen the response and 
avoid collateral damage65. 
 
Analysis of HLA-DR+ APCs showed signs of activation and upregulation of receptors 
important in antigen presentation, suggesting a role for APCs in the tissue in the chronic 
phase of allergic inflammation. As observed in study I, there was an increased expression of 
CD1a on HLA-DR+ cells, in addition to several other genes downstream of IL-4 and IL-13 
showing that “Th2-activated”APCs accumulated in the nasal mucosa during the allergic 
inflammation. However; the contribution of the monocyte/ macrophage population in this 
setting has not been resolved, and which subsets of APCs that contribute to the increase in 
HLA-DR+ APCs was not investigated in this study. Based on our findings in study I it is 
reasonable to assume that CD1c+CD1a+ DCs contribute to this accumulation. Furthermore, 
we have previously shown that pDCs are recruited to the nasal mucosa during an allergic 
inflammatory response183, however no increase was seen in CD141+ DCs (paper I).  
 
CD14+CD68+ macrophages comprise the largest subset of APCs in the upper airway 
mucosa, during steady state184 however their role in an allergic inflammatory response has 
not been investigated. Interestingly, we recently found that in a similar challenge model as in 
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study I, CD14+HLA-DR+ monocytes were recruited to upper airways at an earlier time point 
compared to CD1c+ DCs (Figure 11.), (Eguiluz Garcia et al, unpublished results).  
 
 
 
Figure 11. Early recruitment of CD14+ HLA-DR+ monocytes in human upper airways during 
experimentally induced allergic rhinitis. CD14+ monocytes accumulate in the tissue earlier than 
CD1a+ DCs. 
 
This indicates a division of labor between macrophages and DCs in the allergic inflammatory 
response, where monocytes are recruited to the mucosa in the early phase of the response. 
DCs might be involved in lymph node migration during early responses, and therefore 
accumulate in the mucosa at a later stage when CCR7 is downregulated due to the increased 
presence of the cytokines IL4 and IL13 (study I). This is in line with a study in mice where 
monocyte-derived DCs (moDCs) were sufficient to drive Th2 responses in the mucosa, 
whereas CD11b+ classical DCs induced Th2 responses in the lymph node150. 
 
In addition APCs showed signs of secretion of chemokines such as CCL18, CCL24 and 
CCL17 that attract T cells to the site of inflammation, thus in our model of allergic rhinitis we 
demonstrate the presence of parallel core elements of a Th2 inflammatory response in the 
upper airway mucosa, thus the method can be widened to apply to other cell subsets like 
stromal cells, to reveal functional interactions between novel genes and previously 
recognized members of the allergic cascade. 
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Particularly interesting was the fact that gene expression of four chemokines was 
upregulated. The receptors for these chemokines are CCR3, CCR4, and CCR8; all shown to 
be involved in the recruitment of Th2 cells and eosinophils. These receptor-ligand pairs 
should be tested as targets for therapy in allergic rhinitis, either by blocking the receptor-
ligand interaction or by blocking the local production of these chemokines. Identifying hub 
genes that are central to these processes should be addressed in future studies. 
 
CD1c+ dendritic cells have a potential role in immune regulation and homeostasis in 
human small intestine and upper airway mucosa 
How DCs contribute to the induction and maintenance of tolerance and immune homeostasis 
is a matter of vast investigation. The concept of a tolerogenic DC subset has been proposed 
for a subset of CD103+ DCs in mice, which induces tolerance by induction and activation of 
FoxP3+ Tregs122 123. Whether or not a specific subset of tolerogenic DCs exists in humans 
remains elusive. As previously described DC subsets have a high degree of plasticity and are 
able to change their functional properties in response to environmental signals. Thus different 
subsets might be responsible for induction of tolerogenic responses depending on the signals 
they are exposed to in the environment.  
 
In paper III we identify a subset of CD1c+ DCs present in the upper airway and small 
intestinal mucosa during steady state. These cell express CD1a, initially described on 
Langerhans cells in the skin, but later shown to be expressed on DCs at other sites185, 186, 88.  
 
CD1a is not present on blood DCs, suggesting that CD1a is induced on CD1c+ DCs due to 
factors in the tissue environment. TGF-β is a cytokine that is highly expressed in the mucosa 
at epithelial barrier interfaces during steady state, and a central regulator of immune cell 
development and function. TGF-β is important for induction of regulatory T cells thus 
maintaining immune homeostasis187, 188. We observed that TGF-β induced CD1a on blood 
derived CD1c+ DCs suggesting that TGF-β produced in airway and small intestinal mucosa 
induces CD1a expression on tissue-residing CD1c+ DCs. 
  
HLA-DR molecules are constitutively expressed by DCs and induced together with 
costimulatory molecules on tissue-residing DCs in response to inflammation, thus making the 
cells more efficient in antigen presentation to T cells189. Blood-derived CD1a+CD1c+ DCs 
induced after culture with TGF-β displayed a lower DR expression than their CD1a- 
42 
counterparts, suggesting a lower capacity for antigen presentation and thus activation of T 
cells. Furthermore; CD1a+CD1c+ DCs from the small intestinal mucosa produced less TNF-
α after activation with LPS implying a role for TGF-β in the maintenance of a immune-
regulatory DC subset in the small intestinal and upper airway mucosa.  
 
TGF-β also induced the tyrosine kinase AXL on blood CD1c+ DCs. AXL belongs to the 
family of TAM receptors (Tyrosine, Axl and Mer). These receptors have pivotal roles in 
innate immunity demonstrated by the observation that TAM mutant mice develop severe 
autoimmune diseases190, probably as a combined result of loss of regulation of the innate 
inflammatory responses to pathogens and loss of phagocytosis by DCs and macrophages. The 
innate immune system relies on mechanisms to turn off the response after activation to avoid 
unrestrained signaling and chronic inflammation. TAM receptors prevent this dysregulation 
through induction of SOCS190.  
 
It has been shown that AXL is present on a population of langerhans cell in the skin 
enhancing their capacity for apoptotic cell uptake, and blocking of proinflammatory cytokine 
production. Our findings support the notion that AXL expression on DCs may be an 
important factor for homeostatic maintenance at other sites than the skin.  
 
In conclusion we provide data showing that CD1a is expressed on a subset of mucosal DCs 
with potential functions in immune homeostasis in the small intestinal and upper airway 
mucosa. Future efforts will be aimed at studies of their modulatory effect on T cells. 
 
In summary, studies in this thesis gave new insights into the understanding of the role of a 
subset of DCs in human mucosa during allergic inflammation and immune homeostasis.  
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6. CONCLUSIONS 
 
The work in this thesis has shown that 
 
 A defined subset of CD1c+DCs in human upper airways responds to TSLP and 
activates allergen specific T cells to aggravate an allergic response. 
 
 A defined subset of CD1c+ DCs is present in human upper airways and small 
intestinal mucosa during steady state and may play a role in maintenance of immune 
homeostasis. 
 
 Defined cellular gene networks can be identified in human upper airway mucosa to 
reveal novel pathways involved in the pathogenesis of allergic rhinitis. 
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7. FUTURE PERSPECTIVES 
The central role of DCs in maintenance of immune homeostasis and in the initiation of 
allergic responses makes them attractive targets for intervention to suppress allergic 
inflammatory responses.  
 
The heterogeneity of DCs argues for a division of labor between DCs subsets during steady 
state and possibly also with monocytes recruited to the tissue during allergic inflammation. 
Further investigations on how the different human DC subsets cooperate to mount immune 
protection will be important.  
 
Our understanding of the mechanisms involved in the initiation and development of Th2 
responses in the airway mucosa is advancing, however, much of our knowledge is derived 
from animal studies. Whether these models derived from murine studies are identical in 
humans need further investigation.  
 
In vitro studies have revealed that many allergens can activate epithelial cells, or promote the 
formation of cytokines that activate epithelial cells and DCs. This emerging knowledge of 
stromal cells being important effector cells in the initiation of allergic responses makes the 
study of their function in vivo important. Further investigations on their role in the 
sensitization and effector phase of allergic inflammatory responses should take into account 
that their function relies on the interaction with other immune cells. 
 
The knowledge of DC responses in allergic rhinitis might also have implications for our 
understanding of the pathogenesis of other diseases like allergic asthma, which share many 
features with allergic rhinitis.  
  
45 
8. REFERENCES 
 
1. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296: 301. 
 
2. Janeway CA Jr TP, Walport M, et al The Immune System in Health and Disease.  
Immunobiology; 2001. 
 
3. Iwasaki A, Medzhitov R. Regulation of Adaptive Immunity by the Innate Immune 
System. Science 2010, 327(5963): 291-295. 
 
4. Delves PJ, Roitt IM. The Immune System. New England Journal of Medicine 2000, 
343(1): 37-49. 
 
5. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nature Med 2012, 
18(5): 684-692. 
 
6. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and 
immune homeostasis. Nat Rev Immunol 2014, 14(3): 141-153. 
 
7. Erturk-Hasdemir D, Kasper DL. Resident commensals shaping immunity. Current 
Opinion in Immunology 2013, 25(4): 450-455. 
 
8. Sibilano R, Frossi B, Pucillo CE. Mast cell activation: A complex interplay of positive 
and negative signaling pathways. European Journal of Immunology 2014, 44(9): 
2558-2566. 
 
9. Gri G, Frossi B, D'Incà F, Danelli L, Betto E, Mion F, et al. Mast cell: an emerging 
partner in immune interaction. Frontiers in Immunology 2012, 3. 
 
10. Amin K. The role of mast cells in allergic inflammation. Respiratory Medicine 2012, 
106(1): 9-14. 
 
11. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008, 
9(11): 1215-1223. 
 
12. Lacy P, Davoine F. Eosinophil cytokines: Emerging roles in immunity. Frontiers in 
Immunology 2014, 5. 
 
13. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and 
beyond. Nat Rev Drug Discov 2013, 12(2): 117-129. 
46 
 
14. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the 
molecular age. Nat Rev Immunol 2011, 11(11): 788-798. 
 
15. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. 
Dendritic cells, monocytes and macrophages: a unified nomenclature based on 
ontogeny. Nat Rev Immunol 2014, 14(8): 571-578. 
 
16. Watowich SS, Liu Y-J. Mechanisms regulating dendritic cell specification and 
development. Immunological Reviews 2010, 238(1): 76-92. 
 
17. Sieweke MH, Allen JE. Beyond Stem Cells: Self-Renewal of Differentiated 
Macrophages. Science 2013, 342(6161). 
 
18. Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate Mapping 
Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under 
Homeostasis. Immunity 2013, 38(1): 79-91. 
 
19. Hashimoto D, Chow A, Noizat C, Teo P, Beasley Mary B, Leboeuf M, et al. Tissue-
Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal 
Contribution from Circulating Monocytes. Immunity 2013, 38(4): 792-804. 
 
20. Molawi K, Wolf Y, Kandalla PK, Favret J, Hagemeyer N, Frenzel K, et al. 
Progressive replacement of embryo-derived cardiac macrophages with age. The 
Journal of Experimental Medicine 2014, 211(11): 2151-2158. 
 
21. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin 
to neuropsychiatric disease. Nat Rev Neurosci 2014, 15(5): 300-312. 
 
22. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue 
homeostasis. Nat Rev Immunol 2014, 14(6): 392-404. 
 
23. Bain CC, Bravo-Blas A, Scott CL, Gomez Perdiguero E, Geissmann F, Henri S, et al. 
Constant replenishment from circulating monocytes maintains the macrophage pool in 
the intestine of adult mice. Nat Immunol 2014, 15(10): 929-937. 
 
24. Tamoutounour S, Henri S, Lelouard H, de Bovis B, de Haar C, van der Woude CJ, et 
al. CD64 distinguishes macrophages from dendritic cells in the gut and reveals the 
Th1-inducing role of mesenteric lymph node macrophages during colitis. European 
Journal of Immunology 2012, 42(12): 3150-3166. 
 
47 
25. Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, et al. 
Intestinal Lamina Propria Dendritic Cell Subsets Have Different Origin and 
Functions. Immunity 2009, 31(3): 502-512. 
 
26. Cerovic V, Bain CC, Mowat AM, Milling SWF. Intestinal macrophages and dendritic 
cells: what's the difference? Trends in Immunology 2014, 35(6): 270-277. 
 
27. Gentek R, Molawi K, Sieweke MH. Tissue macrophage identity and self-renewal. 
Immunological Reviews 2014, 262(1): 56-73. 
 
28. Lambrecht B, Guilliams M. Monocytes find a new place to dwell in the niche of 
heartbreak hotel. The Journal of Experimental Medicine 2014, 211(11): 2136. 
 
29. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis 
and disease. Nature 2013, 496(7446): 445-455. 
 
30. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. 
Nat Rev Immunol 2011, 11(11): 723-737. 
 
31. Chanmee T, Ontong P, Konno K, Itano N. Tumor-Associated Macrophages as Major 
Players in the Tumor Microenvironment. Cancers 2014, 6(3): 1670-1690. 
 
32. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. 
functional differentiation. Frontiers in Immunology 2014, 5. 
 
33. Van Dyken SJ, Locksley RM. Interleukin-4- and Interleukin-13-Mediated 
Alternatively Activated Macrophages: Roles in Homeostasis and Disease. Annual 
Review of Immunology 2013, 31(1): 317-343. 
 
34. Segura E, Amigorena S. Inflammatory dendritic cells in mice and humans. Trends in 
Immunology 2013, 34(9): 440-445. 
 
35. Merad M, Sathe P, Helft J, Miller J, Mortha A. The Dendritic Cell Lineage: Ontogeny 
and Function of Dendritic Cells and Their Subsets in the Steady State and the 
Inflamed Setting. Annu Rev Immunol 2013, 31(1): 563-604. 
 
36. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: 
update on Toll-like receptors. Nat Immunol 2010, 11(5): 373-384. 
 
37. Lewis KL, Reizis B. Dendritic Cells: Arbiters of Immunity and Immunological 
Tolerance. Cold Spring Harbor Perspectives in Biology 2012, 4(8). 
48 
 
38. Martín-Fontecha A, Sebastiani S, Höpken UE, Uguccioni M, Lipp M, Lanzavecchia 
A, et al. Regulation of Dendritic Cell Migration to the Draining Lymph Node: Impact 
on T Lymphocyte Traffic and Priming. The Journal of Experimental Medicine 2003, 
198(4): 615-621. 
 
39. Platt AM, Randolph GJ. Chapter Two - Dendritic Cell Migration Through the 
Lymphatic Vasculature to Lymph Nodes. In: Kenneth MM, Miriam M (eds). 
Advances in Immunology, vol. Volume 120. Academic Press, 2013, pp 51-68. 
 
40. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of 
mucosa-associated lymphoid tissue. Mucosal Immunol 2008, 1(1): 31-37. 
 
41. Alberts B JA, Lewis J, Raff M, Roberts K, Walter P. B cells and antibodies.  
Molecular Biology of the cell, vol. 4th edition. Garland Science: New York, 2002. 
 
42. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med 
2012, 18(5): 705-715. 
 
43. Turner DL, Farber DL. Mucosal Resident memory CD4 T cells in protection and 
immunopathology. Frontiers in Immunology 2014, 5. 
 
44. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell 
differentiation: Human memory T-cell subsets. European Journal of Immunology 
2013, 43(11): 2797-2809. 
 
45. von Andrian UH, Mackay CR. T-Cell Function and Migration — Two Sides of the 
Same Coin. New England Journal of Medicine 2000, 343(14): 1020-1034. 
 
46. Hirahara K, Poholek A, Vahedi G, Laurence A, Kanno Y, Milner JD, et al. 
Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated 
disease. Journal of Allergy and Clinical Immunology 2013, 131(5): 1276-1287. 
 
47. O’Shea JJ, Paul WE. Mechanisms Underlying Lineage Commitment and Plasticity of 
Helper CD4+ T Cells. Science 2010, 327(5969): 1098-1102. 
 
48. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly [mdash] 
TFH cells in human health and disease. Nat Rev Immunol 2013, 13(6): 412-426. 
 
49. Teunissen MBM, Haniffa M, Collin MP. Insight into the Immunobiology of Human 
Skin and Functional Specialization of Skin Dendritic Cell Subsets to Innovate 
49 
Intradermal Vaccination Design. In: Teunissen MBM (ed). Intradermal 
Immunization, vol. 351. Springer Berlin Heidelberg, 2012, pp 25-76. 
 
50. Mellman I. Dendritic Cells: Master Regulators of the Immune Response. Cancer 
Immunology Research 2013, 1(3): 145-149. 
 
51. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity 
to viruses. Nat Rev Immunol 2012, 12(2): 136-148. 
 
52. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature 
cytokines in autoimmune and inflammatory diseases. Cytokine 2014(0). 
 
53. Yamane H, Paul WE. Early signaling events that underlie fate decisions of naive 
CD4+ T cells toward distinct T-helper cell subsets. Immunological Reviews 2013, 
252(1): 12-23. 
 
54. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of 
cytokines and transcription factors. Immunological Reviews 2010, 238(1): 247-262. 
 
55. Brucklacher-Waldert V, Carr EJ, Linterman MA, Veldhoen M. Cellular plasticity of 
CD4+ T cells in the intestine. Frontiers in Immunology 2014, 5. 
 
56. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 2009, 20(1): 
4-12. 
 
57. Raphael I, Forsthuber TG. Stability of T-cell lineages in autoimmune diseases. Expert 
Review of Clinical Immunology 2012, 8(4): 299-301. 
 
58. Endo Y, Hirahara K, Yagi R, Tumes DJ, Nakayama T. Pathogenic memory type Th2 
cells in allergic inflammation. Trends in Immunology 2014, 35(2): 69-78. 
 
59. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual Review of 
Immunology 2009, 27(1): 485-517. 
 
60. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, et al. A 
role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clinical & 
Experimental Immunology 2007, 150(3): 407-415. 
 
61. Basu R, Hatton RD, Weaver CT. The Th17 family: flexibility follows function. 
Immunological Reviews 2013, 252(1): 89-103. 
 
50 
62. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper 
T cell population that has abundant production of interleukin 22 and is distinct from 
TH-17, TH1 and TH2 cells. Nat Immunol 2009, 10(8): 864-871. 
 
63. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. 
Immunological Reviews 2013, 252(1): 116-132. 
 
64. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. 
Immunological Reviews 2011, 241(1): 206-227. 
 
65. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T Cells and Immune 
Tolerance. Cell 2008, 133(5): 775-787. 
 
66. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev 
Immunol 2008, 8(7): 523-532. 
 
67. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. 
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 
cells. Nat Med 2013, 19(6): 739-746. 
 
68. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. 
Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine 
Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. The Journal 
of Experimental Medicine 2004, 199(11): 1567-1575. 
 
69. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to 
IL-10–secreting T regulatory cells in high dose allergen exposure. The Journal of 
Experimental Medicine 2008, 205(12): 2887-2898. 
 
70. Tan C, Gery I. The Unique Features of Th9 Cells and their Products. Critical Reviews 
in Immunology 2012, 32(1): 1-10. 
 
71. Temann U-A, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 
cytokine expression, leading to immune pathology. The Journal of Clinical 
Investigation 2002, 109(1): 29-39. 
 
72. Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends in 
Immunology 2014, 35(2): 61-68. 
 
73. Crotty S. T Follicular Helper Cell Differentiation, Function, and Roles in Disease. 
Immunity, 41(4): 529-542. 
51 
 
74. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annual 
Review of Immunology 2003, 21(1): 685-711. 
 
75. Boltjes A, van Wijk F. Human dendritic cell functional specialization in steady-state 
and inflammation. Frontiers in Immunology 2014, 5: 131. 
 
76. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human Tissues 
Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to 
Mouse CD103+ Nonlymphoid Dendritic Cells. Immunity 2012, 37(1): 60-73. 
 
77. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. 
Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116(16): e74-
e80. 
 
78. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ. 
Characterization of human blood dendritic cell subsets. Blood 2002, 100(13): 4512-
4520. 
 
79. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology 2013, 
140(1): 22-30. 
 
80. Cros J, Cagnard N, Woollard K, Patey N, Zhang S-Y, Senechal B, et al. Human 
CD14(dim) Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and 
TLR8 Receptors. Immunity 2010, 33(3): 375-386. 
 
81. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of 
dendritic cells. Frontiers in Immunology 2014, 5. 
 
82. Meixlsperger S, Leung CS, Rämer PC, Pack M, Vanoaica LD, Breton G, et al. 
CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA 
recognition and can be targeted via DEC-205 in humanized mice. Blood 2013, 
121(25): 5034-5044. 
 
83. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human 
CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that 
cross-presents necrotic cell antigens. The Journal of Experimental Medicine 2010, 
207(6): 1247-1260. 
 
84. Yu CI, Becker C, Metang P, Marches F, Wang Y, Toshiyuki H, et al. Human 
CD141+ Dendritic Cells Induce CD4+ T Cells To Produce Type 2 Cytokines. The 
Journal of Immunology 2014, 193(9): 4335-4343. 
52 
 
85. Kitani A, Chua K, Nakamura K, Strober W. Activated Self-MHC-Reactive T Cells 
Have the Cytokine Phenotype of Th3/T Regulatory Cell 1 T Cells. The Journal of 
Immunology 2000, 165(2): 691-702. 
 
86. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunological Reviews 
2010, 234(1): 18-31. 
 
87. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. 
Nat Rev Immunol 2012, 12(8): 557-569. 
 
88. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al. 
Functional Specializations of Human Epidermal Langerhans Cells and CD14+ 
Dermal Dendritic Cells. Immunity 2008, 29(3): 497-510. 
 
89. Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, et al. 
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. 
Nature 2009, 458(7240): 899-903. 
 
90. Lozza L, Farinacci M, Bechtle M, Stäber M, Zedler U, Baiocchini A, et al. 
Communication between Human Dendritic Cell Subsets in Tuberculosis: 
Requirements for Naive CD4(+) T Cell Stimulation. Frontiers in Immunology 2014, 
5: 324. 
 
91. Kassianos AJ, Hardy MY, Ju X, Vijayan D, Ding Y, Vulink AJE, et al. Human CD1c 
(BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory 
phenotype and function in response to Escherichia coli. European Journal of 
Immunology 2012, 42(6): 1512-1522. 
 
92. Van Rhijn I, Ly D, Moody DB. CD1a, CD1b, and CD1c in Immunity Against 
Mycobacteria. In: Divangahi M (ed). The New Paradigm of Immunity to Tuberculosis, 
vol. 783. Springer New York, 2013, pp 181-197. 
 
93. Dillon SM, Rogers LM, Howe R, Hostetler LA, Buhrman J, McCarter MD, et al. 
Human Intestinal Lamina Propria CD1c+ Dendritic Cells Display an Activated 
Phenotype at Steady State and Produce IL-23 in Response to TLR7/8 Stimulation. 
The Journal of Immunology 2010, 184(12): 6612-6621. 
 
94. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. 
Human Inflammatory Dendritic Cells Induce Th17 Cell Differentiation. Immunity 
2013, 38(2): 336-348. 
 
53 
95. Fabricius D, O’Dorisio MS, Blackwell S, Jahrsdörfer B. Human Plasmacytoid 
Dendritic Cell Function: Inhibition of IFN-α Secretion and Modulation of Immune 
Phenotype by Vasoactive Intestinal Peptide. The Journal of Immunology 2006, 
177(9): 5920-5927. 
 
96. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells 
during viral infections, autoimmunity, and tolerance. Immunological Reviews 2010, 
234(1): 142-162. 
 
97. Rönnblom L, Alm GV, Eloranta M-L. The type I interferon system in the 
development of lupus. Seminars in Immunology 2011, 23(2): 113-121. 
 
98. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. 
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. The 
Journal of Experimental Medicine 2005, 202(1): 135-143. 
 
99. Kool M, van Nimwegen M, Willart MAM, Muskens F, Boon L, Smit JJ, et al. An 
Anti-Inflammatory Role for Plasmacytoid Dendritic Cells in Allergic Airway 
Inflammation. the Journal of Immunology 2009, 183(2): 1074-1082. 
 
100. Liu C, Lou Y, Liz, xE, e G, Qin H, et al. Plasmacytoid dendritic cells induce NK cell–
dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice. 
The Journal of Clinical Investigation 2008, 118(3): 1165-1175. 
 
101. Pepper M, Dzierszinski F, Wilson E, Tait E, Fang Q, Yarovinsky F, et al. 
Plasmacytoid Dendritic Cells Are Activated by Toxoplasma gondii to Present Antigen 
and Produce Cytokines. The Journal of Immunology 2008, 180(9): 6229-6236. 
 
102. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid Dendritic Cells: 
Recent Progress and Open Questions. Annual Review of Immunology 2011, 29(1): 
163-183. 
 
103. de Heer HJ, Hammad H, Soullié T, Hijdra D, Vos N, Willart MAM, et al. Essential 
Role of Lung Plasmacytoid Dendritic Cells in Preventing Asthmatic Reactions to 
Harmless Inhaled Antigen. The Journal of Experimental Medicine 2004, 200(1): 89-
98. 
 
104. Palomares O, Rückert B, Jartti T, Kücüksezer UC, Puhakka T, Gomez E, et al. 
Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils 
as potential first-line organs of oral tolerance. Journal of Allergy and Clinical 
Immunology 2012, 129(2): 510-520.e519. 
 
54 
105. Maazi H, Lam J, Lombardi V, Akbari O. Role of plasmacytoid dendritic cell subsets 
in allergic asthma. Allergy 2013, 68(6): 695-701. 
 
106. Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE. Revised map of the 
human progenitor hierarchy shows the origin of macrophages and dendritic cells in 
early lymphoid development. Nat Immunol 2010, 11(7): 585-593. 
 
107. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, et al. 
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic 
progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95(11): 3489-
3497. 
 
108. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, et al. 
Flt3-Ligand and Granulocyte Colony-Stimulating Factor Mobilize Distinct Human 
Dendritic Cell Subsets In Vivo. The Journal of Immunology 2000, 165(1): 566-572. 
 
109. Tussiwand R, Onai N, Mazzucchelli L, Manz MG. Inhibition of natural type I IFN-
producing and dendritic cell development by a small molecule receptor tyrosine 
kinase inhibitor with Flt3 affinity. J Immunol 2005, 175: 3674 - 3680. 
 
110. Bigley V, Haniffa M, Doulatov S, Wang X-N, Dickinson R, McGovern N, et al. The 
human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. Journal 
of Experimental Medicine, 208(2): 227-234. 
 
111. Collin M, Bigley V, Haniffa M, Hambleton S. Human dendritic cell deficiency: the 
missing ID? Nature Rev Immunol 2011, 11(9): 575-583. 
 
112. Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Locksley R, et al. Transcription 
Factor E2-2 Is an Essential and Specific Regulator of Plasmacytoid Dendritic Cell 
Development. Cell 2008, 135(1): 37-48. 
 
113. Shortman K, Sathe P, Vremec D, Naik S, O’Keeffe M. Chapter Four - Plasmacytoid 
Dendritic Cell Development. In: Kenneth MM, Miriam M (eds). Advances in 
Immunology, vol. Volume 120. Academic Press, 2013, pp 105-126. 
 
114. Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, et al. 
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent 
dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012, 119(25): 6052-
6062. 
 
115. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 
Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse 
Control Mucosal IL-17 Cytokine Responses. Immunity 2013, 38(5): 970-983. 
55 
 
116. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez 
P, et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) 
defines the classical dendritic cell lineage. The Journal of Experimental Medicine 
2012, 209(6): 1153-1165. 
 
117. Satpathy AT, KC W, Albring JC, Edelson BT, Kretzer NM, Bhattacharya D, et al. 
Zbtb46 expression distinguishes classical dendritic cells and their committed 
progenitors from other immune lineages. The Journal of Experimental Medicine 2012, 
209(6): 1135-1152. 
 
118. Merad M, Manz MG. Dendritic cell homeostasis. Blood 2009, 113(15): 3418-3427. 
 
119. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. Langerhans 
cells renew in the skin throughout life under steady-state conditions. Nat Immunol 
2002, 3(12): 1135-1141. 
 
120. Kanitakis J, Morelon E, Petruzzo P, Badet L, Dubernard J-M. Self-renewal capacity 
of human epidermal Langerhans cells: observations made on a composite tissue 
allograft. Experimental Dermatology 2011, 20(2): 145-146. 
 
121. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive Presentation of a 
Natural Tissue Autoantigen Exclusively by Dendritic Cells in the Draining Lymph 
Node. The Journal of Experimental Medicine 2002, 196(8): 1079-1090. 
 
122. Worthington JJ, Czajkowska BI, Melton AC, Travis MA. Intestinal Dendritic Cells 
Specialize to Activate Transforming Growth Factor-β and Induce Foxp3+ Regulatory 
T Cells via Integrin αvβ8. Gastroenterology 2011, 141(5): 1802-1812. 
 
123. Coombes JL, Siddiqui KRR, Arancibia-Carcamo CV, Hall J, Sun C-M, Belkaid Y, et 
al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ 
regulatory T cells via a TGF-B and retinoic acid-dependent mechanism. Journal of 
Experimental Medicine 2007, 204(8): 1757-1764. 
 
124. Huang L, Baban B, Johnson BA, Mellor AL. Dendritic Cells, Indoleamine 2,3 
Dioxygenase and Acquired Immune Privilege. International Reviews of Immunology 
2010, 29(2): 133-155. 
 
125. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MBA, Lemke G. TAM Receptors Are 
Pleiotropic Inhibitors of the Innate Immune Response. Cell 2007, 131(6): 1124-1136. 
 
56 
126. Bauer T, Zagòrska A, Jurkin J, Yasmin N, Kõffel R, Richter S, et al. Identification of 
Axl as a downstream effector of TGF- B during Langerhans cell differentiation and 
epidermal homeostasis. Journal of Experimental Medicine 2012, 209(11): 2033-2047. 
 
127. Papadopoulos N, Agache I, Bavbek S, Bilo B, Braido F, Cardona V, et al. Research 
needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and 
Translational Allergy 2012, 2(1): 21. 
 
128. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert 
C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 
years and future needs. Journal of Allergy and Clinical Immunology 2012, 130(5): 
1049-1062. 
 
129. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 
2008, 454(7203): 445-454. 
 
130. Hamilton RG. Allergic sensitization is a key risk factor for but not synonymous with 
allergic disease. Journal of Allergy and Clinical Immunology 2014, 134(2): 360-361. 
 
131. KleinJan A, Vinke J, Severijnen L, Fokkens W. Local production and detection of 
(specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. European 
Respiratory Journal 2000, 15(3): 491-497. 
 
132. Smurthwaite L, Walker SN, Wilson DR, Birch DS, Merrett TG, Durham SR, et al. 
Persistent IgE synthesis in the nasal mucosa of hay fever patients. European Journal 
of Immunology 2001, 31(12): 3422-3431. 
 
133. Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, et al. Allergen 
Drives Class Switching to IgE in the Nasal Mucosa in Allergic Rhinitis. The Journal 
of Immunology 2005, 174(8): 5024-5032. 
 
134. Jay D, Nadeau K. Immune Mechanisms of Sublingual Immunotherapy. Current 
Allergy and Asthma Reports 2014, 14(11): 1-7. 
 
135. Ober C, Yao T-C. The genetics of asthma and allergic disease: a 21st century 
perspective. Immunological Reviews 2011, 242(1): 10-30. 
 
136. Ortiz RA, Barnes KC. Genetics of Allergic Diseases. Immunology and Allergy Clinics 
of North America 2015, 35(1): 19-44. 
 
57 
137. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et 
al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse 
North American populations. Nat Genet 2011, 43(9): 887-892. 
 
138. Holt PG, Van Den Biggelaar AHJ. 99th Dahlem Conference on Infection, 
Inflammation and Chronic Inflammatory Disorders: The role of infections in allergy: 
atopic asthma as a paradigm. Clinical & Experimental Immunology 2010, 160(1): 22-
26. 
 
139. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989, 299(6710): 1259-
1260. 
 
140. Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R, et al. Factors 
responsible for differences between asymptomatic subjects and patients presenting an 
IgE sensitization to allergens. A GA2LEN project. Allergy 2006, 61(6): 671-680. 
 
141. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012, 18(5): 693-
704. 
 
142. Lambrecht BN, Salomon Bt, Klatzmann D, Pauwels RA. Dendritic Cells Are 
Required for the Development of Chronic Eosinophilic Airway Inflammation in 
Response to Inhaled Antigen in Sensitized Mice. The Journal of Immunology 1998, 
160(8): 4090-4097. 
 
143. van Rijt LS. In vivo depletion of lung CD11c+ dendritic cells during allergen 
challenge abrogates the characteristic features of asthma. J Exp Med 2005, 201: 981-
991. 
 
144. Fokkens WJ, Vroom TM, Rijntjes E, Mulder PGH. Fluctuation of the number of CD-
1(T6)-positive dendritic cells, presumably Langerhans cells, in the nasal mucosa of 
patients with an isolated grass-pollen allergy before, during, and after the grass-pollen 
season. Journal of Allergy and Clinical Immunology 1989, 84(1): 39-43. 
 
145. KleinJan A, Willart M, van Rijt LS, Braunstahl G-J, Leman K, Jung S, et al. An 
essential role for dendritic cells in human and experimental allergic rhinitis. Journal 
of Allergy and Clinical Immunology 2006, 118(5): 1117-1125. 
 
146. Golebski K, Röschmann KIL, Toppila-Salmi S, Hammad H, Lambrecht BN, 
Renkonen R, et al. The multi-faceted role of allergen exposure to the local airway 
mucosa. Allergy 2012, 68(2): 152-160. 
 
147. Lambrecht BN, Hammad H. Asthma: The importance of dysregulated barrier 
immunity. European Journal of Immunology 2013, 43(12): 3125-3137. 
58 
 
148. Salazar F, Ghaemmaghami A. Allergen recognition by innate immune cells: critical 
role of dendritic and epithelial cells. Frontiers in Immunology 2013, 4. 
 
149. Georas SN, Rezaee F. Epithelial barrier function: At the front line of asthma 
immunology and allergic airway inflammation. Journal of Allergy and Clinical 
Immunology 2014, 134(3): 509-520. 
 
150. Plantinga M, Guilliams M, Vanheerswynghels M, Deswarte K, Branco-Madeira F, 
Toussaint W, et al. Conventional and Monocyte-Derived CD11b+ Dendritic Cells 
Initiate and Maintain T Helper 2 Cell-Mediated Immunity to House Dust Mite 
Allergen. Immunity 2013, 38(2): 322-335. 
 
151. Hammad H, Plantinga M, Deswarte K, Pouliot P, Willart MAM, Kool M, et al. 
Inflammatory dendritic cells - not basophils - are necessary and sufficient for 
induction of Th2 immunity to inhaled house dust mite allergen. J Exp Med 2010, 
207(10): 2097-2111. 
 
152. Kim Y-G, Udayanga Kankanam Gamage S, Totsuka N, Weinberg Jason B, Núñez G, 
Shibuya A. Gut Dysbiosis Promotes M2 Macrophage Polarization and Allergic 
Airway Inflammation via Fungi-Induced PGE2. Cell Host & Microbe 2014, 15(1): 
95-102. 
 
153. Hosier S, Nelson A, Foxworthe D, Friend SL, Williams DE, Farr A. A thymic stromal 
cell line supports in vitro development of surface IgM+ B cells and produces a novel 
growth factor affecting B and T lineage cells. Experimental hematology 1994, 22(3): 
321-328. 
 
154. Liu YJ. TSLP: an epithelial cell cytokine that regulates T cell differentiation by 
conditioning dendritic cell maturation. Annu Rev Immunol 2007, 25: 193-219. 
 
155. Ito T. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell 
response through OX40 ligand. J Exp Med 2005, 202: 1213-1223. 
 
156. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human 
epithelial cells trigger dendritic cell-mediated allergic inflammation by producing 
TSLP. Nat Immunol 2002, 3(7): 673-680. 
 
157. Rochman Y, Kashyap M, Robinson GW, Sakamoto K, Gomez-Rodriguez J, Wagner 
K-U, et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via 
kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc 
Natl Acad Sci USA 2010, 107(45): 19455-19460. 
 
59 
158. Arima K, Watanabe N, Hanabuchi S, Chang M, Sun S-C, Liu Y-J. Distinct Signal 
Codes Generate Dendritic Cell Functional Plasticity. Sci Signal 2010, 3(105): ra4. 
 
159. Ying S, O’Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, et al. Thymic Stromal 
Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with 
Expression of Th2-Attracting Chemokines and Disease Severity. The Journal of 
Immunology 2005, 174(12): 8183-8190. 
 
160. Kato A, Favoreto S, Avila PC, Schleimer RP. TLR3- and TH2 cytokine-dependent 
production of thymic stromal lymphopoietin in human airway epithelial cells. J 
Immunol 2007, 179: 1080-1087. 
 
161. Kouzaki H, O'Grady SM, Lawrence CB, Kita H. Proteases Induce Production of 
Thymic Stromal Lymphopoietin by Airway Epithelial Cells through Protease-
Activated Receptor-2. J Immunol 2009, 183(2): 1427-1434. 
 
162. Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM, et al. Human 
intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. 
2009. pp. 1481-1489. 
 
163. Spadoni I, Iliev ID, Rossi G, Rescigno M. Dendritic cells produce TSLP that limits 
the differentiation of Th17 cells, fosters Treg development, and protects against 
colitis. Mucosal Immunol 2012, 5(2): 184-193. 
 
164. Harada M, Hirota T, Jodo AI, Doi S, Kameda M, Fujita K, et al. Functional Analysis 
of the Thymic Stromal Lymphopoietin Variants in Human Bronchial Epithelial Cells. 
Am J Respir Cell Mol Biol 2009, 40(3): 368-374. 
 
165. Bjerkan L, Schreurs O, Engen SA, Jahnsen FL, Baekkevold ES, Blix IJ, et al. The 
short form of TSLP is constitutively translated in human keratinocytes and has 
characteristics of an antimicrobial peptide. Mucosal Immunol 2014. 
 
166. Xie Y, Takai T, Chen X, Okumura K, Ogawa H. Long TSLP transcript expression 
and release of TSLP induced by TLR ligands and cytokines in human keratinocytes. 
Journal of Dermatological Science 2012, 66(3): 233-237. 
 
167. van Helden MJ, Lambrecht BN. Dendritic cells in asthma. Current Opinion in 
Immunology 2013, 25(6): 745-754. 
 
168. Godthelp T, Fokkens WJ, Kleinjan A, Holm AF, Mulder PGH, Prens EP, et al. 
Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during 
allergen provocation. Clinical & Experimental Allergy 1996, 26(6): 677-688. 
60 
 
169. Lambrecht BN, Hammad H. Allergens and the airway epithelium response: Gateway 
to allergic sensitization. Journal of Allergy and Clinical Immunology 2014, 134(3): 
499-507. 
 
170. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. Journal of Allergy 
and Clinical Immunology 2012, 130(4): 845-852. 
 
171. Kitajima M, Ziegler SF. Cutting edge: identification of the thymic stromal 
lymphopoietin-responsive dendritic cell subset critical for initiation of type 2 contact 
hypersensitivity. Journal of immunology 2013, 191(10): 4903-4907. 
 
172. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory 
dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. 
J Exp Med 2001, 193: 51-60. 
 
173. Till SJ, Jacobson MR, Brien FO, Durham SR, KleinJan A, Fokkens WJ, et al. 
Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic 
rhinitis and effects of topical corticosteroid therapy. Allergy 2001, 56(2): 126-131. 
 
174. Agea E, Russano A, Bistoni O, Mannucci R, Nicoletti I, Corazzi L, et al. Human 
CD1-restricted T cell recognition of lipids from pollens. Journal of Experimental 
Medicine 2005, 202(2): 295-308. 
 
175. Veres TZ, Voedisch S, Spies E, Valtonen J, Prenzler F, Braun A. Aeroallergen 
Challenge Promotes Dendritic Cell Proliferation in the Airways. The Journal of 
Immunology 2013, 190(3): 897-903. 
 
176. Jemima EA, Prema A, Thangam EB. Functional characterization of histamine H4 
receptor on human mast cells. Molecular Immunology 2014, 62(1): 19-28. 
 
177. Junttila IS, Watson C, Kummola L, Chen X, Hu-Li J, Guo L, et al. Efficient cytokine-
induced IL-13 production by mast cells requires both IL-33 and IL-3. Journal of 
Allergy and Clinical Immunology 2013, 132(3): 704-712.e710. 
 
178. Pedroza-Gonzalez A, Xu K, Wu T-C, Aspord C, Tindle S, Marches F, et al. Thymic 
stromal lymphopoietin fosters human breast tumor growth by promoting type 2 
inflammation. The Journal of Experimental Medicine 2011, 208(3): 479-490. 
 
179. Comeau MR, Ziegler SF. The influence of TSLP on the allergic response. Mucosal 
Immunol 2009, 3(2): 138-147. 
 
61 
180. Moret FM, Radstake TRDJ, van Roon JAG. Targeting Th2-typified immune 
responses to prevent immunopathology in rheumatic diseases: belittled therapeutic 
strategies? Annals of the Rheumatic Diseases 2013. 
 
181. Gauvreau GM, O'Byrne PM, Boulet L-P, Wang Y, Cockcroft D, Bigler J, et al. 
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. New 
England Journal of Medicine 2014, 370(22): 2102-2110. 
 
182. Watson B, Gauvreau GM. Thymic stromal lymphopoietin: a central regulator of 
allergic asthma. Expert Opinion on Therapeutic Targets 2014, 18(7): 771-785. 
 
183. Jahnsen FL, Lund-Johansen F, Dunne JF, Farkas L, Haye R, Brandtzaeg P. 
Experimentally Induced Recruitment of Plasmacytoid (CD123high) Dendritic Cells in 
Human Nasal Allergy. J Immunology 2000, 165(7): 4062-4068. 
 
184. Jahnsen FL, Gran E, Haye R, Brandtzaeg P. Human Nasal Mucosa Contains Antigen-
Presenting Cells of Strikingly Different Functional Phenotypes. Am J Respir Cell Mol 
Biol 2004, 30(1): 31-37. 
 
185. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, et al. 
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens 
to T cells. The Journal of Clinical Investigation 2004, 113(5): 701-708. 
 
186. Indrasingh I, Chandi G, Jeyaseelan L, Vettivel S, Chandi SM. Quantitative analysis of 
CD1a (T6) positive Langerhans cells in human tonsil epithelium. Annals of Anatomy - 
Anatomischer Anzeiger 1999, 181(6): 567-572. 
 
187. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor 
function and Foxp3 expression in CD4+CD25+ regulatory T cells. The Journal of 
Experimental Medicine 2005, 201(7): 1061-1067. 
 
188. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting 
Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 
Induction and Down-Regulation of Smad7. The Journal of Immunology 2004, 172(9): 
5149-5153. 
 
189. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting 
cells: can anything replace a dendritic cell? Nat Rev Immunol 2014, 14(11): 719-730. 
 
190. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nature Rev Immunol 
2008, 8(5): 327-336. 
  
62 
ERRATA 
Please note the following corrections to the thesis: 
Spaces have been added between paragraphs. 
1.1 
 Page1: B-cells changed to B cells 
1.2.1 
 Page 4: “Eosinophils was shown to be” changed to “were shown to be” and  
“Tissue residing macrophages was initially” changed to “were initially” 
Page 6: “These findings primarily derive from in vitro experiments...” changed to 
“These findings are primarily derived from…” 
1.2.2 
Page 8: “differentiation49 Thus DCs determine…” changed to“differentiation49. Thus 
DCs…” 
Page 9:”Therefore these cells are crucial for host defense but are also implicated in 
immune-mediated disease like allergy and autoimmune disease.” sentence rephrased 
to“…to promote local immune responses (Figure 3)40, thus they are crucial for host 
defense. CD4+ helper T cells are also implicated in immune-mediated diseases like 
allergy and autoimmune disease46.” 
1.3.2 
Page 15 “Resident CD141+DCs was shown to” changed to “were shown to” Page 16: 
“CD1c+ DCs was shown to display” changed to “were shown to display” and 
“Furthermore; pDCs has been implicated” changed to “have been”  
 Page 18: not able changed to unable  
Page 18: “animal studies have shown that they are” changed to “animal studies have 
shown that LCs are”  
1.4 
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Page 20: “Furthermore; receptors” changed to “Furthermore, receptors”, “block 
proinflammatory cytokine production” changed to “blocks proinflammatory” and 
inhibits changed to inhibit 
1.5.1 
Page 21: “genetically susceptible individuals reacts” changed to “individuals react”, 
“However; it is important to emphasize” changed to “However, it is important to 
emphasize”and “In addition, local class switching to IgE may takes place” changed 
to “may take”. 
Page 22:“Genome-wide association studies (GWAS) allows for” changed to “allow 
for” 
1.5.3 
Page 25: “during pollens seasons” changed to “during pollen season” and 
“initiation of allergic responses144Furthermore” point added in between sentences 
and changed to “initiation of allergic responses144. Furthermore” 
3.1 
 Page 30: “allergic volunteers was included” changed to “were included” 
3.3 
Page 31: “In paper II a defined cell subsets” changed to: “In paper II, defined cell 
subsets” 
 Page 32: avaable changed to available 
3.4 
Page 32: staning changed to staining and;”To control for” changed to “As a control 
for” 
 
3.5 Page 33: “Using flow cytometric analysis it is possible to study large amounts of cells 
and several different markers in the same sample, and it is a sensitive technique that 
allows for the detection of relatively rare cell subsets” changed to “Flow cytometry 
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allows for the study of large amounts of cells and several different markers in the 
same sample. It is a sensitive technique that makes it possible to detect relatively rare 
cell subsets”.  
4.2 
 Page 35: Human beings changed to humans 
4.3  
Page 36: “DCs display properties suggesting involvement role in immune regulation”, 
role deleted. 
5 
 Page 40: activation of effector T cells are changed to is 
 
8  Two duplicated references were removed: 
124. Worthington JJ, Czajkowska BI, Melton AC, Travis MA. Intestinal Dendritic 
Cells Specialize to Activate Transforming Growth Factor-β and Induce Foxp3(+) 
Regulatory T Cells via Integrin αvβ8. Gastroenterology 2011, 141(5): 1802-1812. 
158. Ito T, Wang Y-H, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. 
TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response 
through OX40 ligand. Journal of Experimental Medicine 2005, 202(9): 1213-1223. 
Page 50 Reference # 74; RM S, DH, MC N changed to Steinman RM, Hawiger D, 
Nussenzweig MC 
Page 51 Reference # 85; A K, K C, K N, W S changed to Kitani A, Chua K, Nakamura 
K, Strober W. 
Page 60 Reference # 189 JC M, JJ L, M G, AY R changed to Marie JC, Letterio JJ, 
Gavin M, Rudensky AY 
Page 61 Reference #190 MC F, C B, G M, F P, PR G, MF N changed to Fantini MC, Becker 
C, Monteleone G, Pallone F, Galle PR, Neurath MF 
